

# Curriculum Vitae – João Conde, PhD

## PERSONAL DETAILS

Name: João Diogo Osório de Castro Conde

Date of Birth: February 5<sup>th</sup> 1982, Lisbon, Portugal.

Languages: Portuguese (Native)

English (Proficient)

Spanish (Proficient)

Professional Website: <https://www.onconanolab.com/>

Contact: [joao.conde@nms.unl.pt](mailto:joao.conde@nms.unl.pt) ; [joaodconde@gmail.com](mailto:joaodconde@gmail.com)

ORCID: [0000-0001-8422-6792](https://orcid.org/0000-0001-8422-6792) ; Scopus ID: [56992468300](https://scopus.com/authid/detail.url?authorID=56992468300)

Hobby: Painting



## SUMMARY

João Conde is a **Group Leader (Cancer NanoMedicine Lab)** at **Comprehensive Health Research Centre (CHRC) - NOVA Medical School**, **Full Professor of Precision Medicine and Oncogenomics** in Mestrado Integrado em Medicina at **NOVA Medical School, Universidade Nova de Lisboa**. He holds a **Habilitation (Agregação) in Biomedicine (2023)**, with a **specialization in Precision Medicine and Oncogenomics**. His expertise spans **oncogenomics, nanomedicine and gene therapy, with a strong focus on precision medicine in oncology**.

In 2013, he received his **PhD in Biology**, specializing in Nanobiotechnology, from the **Universidade Nova de Lisboa** and the **Universidad de Zaragoza**, under the **FP7 European Consortium NanoScieE<sup>+</sup> – NANOTRUCK: multifunctional nanoparticles for gene silencing**. After, he was a **Marie Curie Fellow** at the **Massachusetts Institute of Technology, Harvard-MIT Division for Health Sciences and Technology**, and **School of Engineering and Materials Science at Queen Mary University of London**. From 2017 to 2019, he was a **Junior Investigator** at **Instituto de Medicina Molecular**. **In 2019, he won an ERC Starting Grant (1.5M€) from the European Research Council** to build a genetic biobarcode to profile breast cancer heterogeneity. **Since receiving the ERC Starting Grant, he has mentored more than 20 students and post-docs (including 2 Marie Curie fellows)**. Since his **PhD**, he has published **more than 80 publications in journals with impact factors (IF) >15**, and since his **Habilitation (Agregação) in Biomedicine**, he has published **more than 35 publications in top-tier journals**. Moreover, he is also a **leader of multidisciplinary research teams and projects in precision medicine, oncogenomics and nanomedicine**.

He is also a **co-founder and shareholder of the biotech company TargTex, Targeted Therapeutics for Glioblastoma Multiforme**. Since 2020, he has also been a **senior member of the Global Burden of Disease (GBD) Consortium** at the **Institute for Health Metrics and Evaluation (IHME), University of Washington**. In 2023, he partnered with **Vector Bioscience Cambridge and AstraZeneca to develop RNA-based cancer therapies from the European Innovation Council (2.5M€)**. In 2023, was elected for the **Scientific Advisory Board of FCT: Fundação para a Ciência e a Tecnologia**. Since 2024, he has been a member of the **Lisbon Academy of Sciences** and has been on the **Scientific Advisory Board of Vector Bioscience Cambridge**. From March 2024 to November 2025, he was the **Vice Dean for Research at NOVA Medical School**. In 2025, NOVA Medical School was awarded ~6.5M€ (**FEDER and Haddad Foundation**) to build a **preclinical-to-clinical hub and a medical innovation center, with João Conde as**

**one of the scientific coordinators.** Since March 2026, he is also a member of the **Research & Development Working Group I team**, part of the **National Program for Oncological Diseases at the Directorate-General for Health.**

The main aspects related to the recognition and diffusion of his early contributions are: **more than 180 articles (average impact factor of >25 in the last 5 years) in top-tier journals** of *Cancer Therapy, Oncology, Precision Medicine, Nanotechnology/Materials Science and NanoMedicine (Nature, Science, The Lancet, Nature Medicine, Nature Materials, Nature Reviews Materials, The Lancet Oncology, Nature Nanotechnology, JAMA Oncology, Science Advances, Nature Communications, The Lancet Gastroenterol Hepatol, Nature Rev Methods Primers, PNAS, Accounts of Chemical Research, The Lancet Child Adolesc Health, Progress in Materials Science, ACS Nano, Advanced Materials, JACS, Angewandte Chemie, Advanced Functional Materials, Trends in Cancer, Trends in Biotechnology, Biomaterials, etc.)*, **more than 30 articles are as 1<sup>st</sup> author and more than 85 articles as corresponding author, cited more than 33000 times (h-index 71).** **Nearly 45** of them have been selected as **Covers** of Journals such as *Nature Nanotechnology* (COVID-19 Special Issue), *Nature Materials, The Lancet, The Lancet Oncology, The Lancet Public Health, Advanced Materials, The Lancet Neurology, ACS Nano, Adv. Functional Materials, JAMA Oncology, JACC, Trends in Cancer, BioTechniques*, etc. He is also a member of the **editorial board of several international journals** and **editor and reviewer for leading journals** such as *Nature Reviews Cancer, Nature Materials, Nature Biotechnology, Nature Communications, Nature Protocols, Nature Reviews Bioengineering, PNAS, Accounts Chemical Research, Chemical Reviews ACS Nano, Advanced Materials*, among others.

In addition, **12 international patents** on nanomedicine-based platforms for cancer therapy and diagnosis were submitted and/or approved. He was also awarded **several international awards**, including the **2024, 2023 and 2022 World's Top 2% Scientists list by Stanford University**, the **2021 Biomaterials Science Emerging Investigator**, the **2021 Top 2% Most cited in Nanoscience/Nanotechnology from PLOS Biology**, the **Nanomaterials 2020 Young Investigator Award**, the **Wellcome Image Awards 2017**, the **2016 Nano-Micro Letters Researcher Award** and the **2016 National Cancer Institute Image award**.

Teaching activities include lectures and courses across multiple programs at **NOVA Medical School** and other faculties within Universidade NOVA de Lisboa. In 2020, João Conde began teaching **Genetics** in the **Master in Medicine (Mestrado Integrado em Medicina)** at **NOVA Medical School**, followed in 2021 by contributions to the **Master in Biochemistry for Health (Human Genetics, ITQB-NOVA, and NOVA Medical School)** and the **International Master in Biomedical Research (Translational and Precision Medicine)**. Since 2022, he has been teaching in the **PhD in Health Sciences** at **NOVA Medical School**, focusing on **New Cellular and Molecular Therapies**. In 2025, this role expanded further to include invited classes in the **Master in Medicine (Mestrado Integrado em Medicina)**, **Digital Health** curricular unit, and the **Master in Impact Entrepreneurship and Innovation** and the **Master in Clinical Research Management** at **NOVA School of Business and Economics** and **NOVA Medical School**, within the **Medical Advances Specifics** curricular unit. Also in 2026, included also invited classes in the **Aging, Inflammation, and Disease** curricular unit, from the **PhD Program in Health Sciences**. This teaching trajectory highlights consistent engagement in multidisciplinary education spanning genetics, nanomedicine, molecular biology, precision medicine and innovation, contributing to both basic and advanced biomedical training at the undergraduate, master's and doctoral levels.

## **EDUCATION**

- **Habilitation** (Agregação) in **Biomedicine**, with a specialization in **Precision Medicine**, **NOVA Medical School, Universidade Nova de Lisboa**, Portugal, 2023.
- **PhD in Biology**, Specialty **Nanobiotechnology**, *Summa cum laude*, **Universidade Nova de Lisboa**, Portugal and **Instituto de Nanociencia de Aragón** at **Zaragoza University**, Spain, 2013.
- **MSc in Biology**, *Summa cum laude*, **Universidade Lusófona de Humanidades e Tecnologias**, Portugal, 2008.

## **CURRENT POSITIONS**

- Mar 2026 – Present: **Member** at **Research & Development Working Group I**, part of the **National Program for Oncological Diseases** at the **Directorate-General for Health**.
- Mar 2026 – Present: **Member** at **Faculty Council** at **NOVA Medical School, Universidade Nova de Lisboa** (Portugal).
- July 2025 – Present: **Full Professor** at **NOVA Medical School, Universidade Nova de Lisboa** (Portugal).
- July 2024 – Present: **Partner of UPIC Cancer**, United to End Cancer Portugal-USA Cancer Initiative (Portugal-USA).
- January 2024 – Present: **Scientific Advisory Board** at **Vector Bioscience Cambridge** (UK).
- November 2023 – Present: **Coordination member** of the Drug Discovery and Advanced Therapies group of the **NOVA Health Strategic Platform** at **Universidade Nova de Lisboa** (Portugal).
- March 2020 – Present: **Senior Member** of the **Global Burden Disease (GBD)**, at the **Institute for Health Metrics and Evaluation (IHME)**, University of Washington (US).
- February 2020 – Present: **Group Leader** (OncoNano Lab), **NOVA Medical School, Universidade Nova de Lisboa** (Portugal).
- February 2020 – June 2025: **Assistant Professor** at **NOVA Medical School, Universidade Nova de Lisboa** (Portugal).
- September 2019 – Present: Co-founder and Shareholder of **TargTex SA start-up company: Targeted therapies for the treatment of brain cancer** (Portugal).

## **PREVIOUS POSITIONS**

- March 2023 – April 2026: **Scientific Advisory Board** (Health and Life Sciences board) at **FCT: Fundação para a Ciência e a Tecnologia** (Portugal).
- March 2024 – November 2025: **Vice-Dean for Research** at **NOVA Medical School, Universidade Nova de Lisboa** (Portugal).
- March 2024 – November 2025: **Steering Committee** at **NOVA Medical School, Universidade Nova de Lisboa** (Portugal).
- March 2024 – November 2025: **Value Creation Council** at **Universidade Nova de Lisboa** (Portugal).
- March 2024 – November 2025: **Strategic Council for Innovation** at **Universidade Nova de Lisboa** (Portugal).
- October 2017 – January 2020: **Junior Researcher** at **Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa** (Portugal).
- April 2016 – April 2017: **Marie Curie Early-Stage Career Fellow** at School of Engineering and Materials Science at **Queen Mary University London** (UK).

- February 2014 – April 2016: **Marie Curie Early-Stage Career Fellow** at the **Massachusetts Institute of Technology (MIT), Harvard–MIT Division for Health Sciences and Technology, Institute for Medical Engineering and Science (US)**.
- January 2010 – December 2013: **Science and Technology Foundation PhD Fellow (FCT, SFRH/BD/ 62957/2009)**, **Universidade Nova de Lisboa (Portugal)** and **Zaragoza University (Spain)**.
- January 2009 – January 2010: Research fellowship (PTDC/BIO/66514/2006), Research Center for Human Molecular Genetics, **FCT/UNL, Universidade Nova de Lisboa (Portugal)**.
- September 2007 – December 2008: Under-graduate fellowship, Molecular Genetics Department at **NOVA Medical School, Universidade Nova de Lisboa (Portugal)**.

## **BACKGROUND**

- Cancer Nanomedicine, Nanotechnology and Materials Science.
- Precision Medicine and Oncogenetics/Oncogenomics.
- Oncology and Biomedicine.
- Multifunctional nanomaterials for Cancer therapy and diagnostics.
- Genetic therapies based on DNA/RNA, siRNA/miRNA.
- Gene therapy, drug delivery, tumor targeting.
- Smart clinical platforms based on new materials and technologies for local therapy in cancer.
- Gene therapy/Antisense DNA/RNA Interference/microRNA, gene editing CRISPR/Cas9.
- *In vivo* cancer mouse models (breast, colon, gastric, liver, glioblastoma, prostate, pancreatic, ovarian and lung cancer) – tumour induction and administration (systemic and local) of anti-cancer therapies.
- Translational research and clinical applications of nanomedicine and precision oncology.
- Machine learning and AI in nanomedicine, computational modeling for nanomaterial optimization.
- Public health and epidemiology, expertise in *Global Burden of Disease (GBD)* research.
- Regenerative medicine and tissue engineering, biomimetic hydrogels and scaffold-based therapies.
- Immunotherapy and immune engineering, macrophage-targeted and nanovaccine therapies.
- Biomedical imaging and theranostics, development of tumor-tracking and image-guided therapies.
- Bioconjugation and bioengineering, functionalized nanomaterials for controlled drug release.
- Emerging technologies in medicine, smart theranostics, and opto-theranostics.

## **TEACHING**

- 2026 – Present: Invited classes in the **Ageing, Inflammation, and Disease** curricular unit, from the **PhD Program in Health Sciences, NOVA Medical School, Universidade NOVA de Lisboa**.
- 2025 – Present: Invited classes of the **Master Course in Medicine** (Unidade Curricular de Saúde Digital do Mestrado Integrado em Medicina), **NOVA Medical School, Universidade NOVA de Lisboa**.
- 2025 – Present: Invited classes of the **Master in Impact Entrepreneurship and Innovation** and **Master in Clinical Research Management**, Curricular Unit Medical Advances Specifics, **NOVA School of Business and Economics** and **NOVA Medical School, Universidade NOVA de Lisboa**.
- 2022 – Present: Invited classes of the **PhD in Health Sciences**, Curricular Unit New Cellular and Molecular Therapies, **NOVA Medical School, Universidade NOVA de Lisboa**.
- 2021 – Present: Invited classes of the **Master in Biochemistry for Health**, **FCT/UNL**, Curricular Unit Human Genetics, **ITQB-NOVA** and **NOVA Medical School, Universidade NOVA de Lisboa**.
- 2021 – Present: Invited classes of the **Bachelor in Biology**, **ISPA - Instituto Universitário de Ciências Psicológicas, Sociais e da Vida**.

- 2021 – Present: Invited classes of the **International Master in Biomedical Research**, Curricular Unit Translational & Precision Medicine, **NOVA Medical School, Universidade NOVA de Lisboa**.
- 2020 – Present: **Genetics of the Master in Medicine** (Unidade Curricular de Genética do Mestrado Integrado em Medicina), **NOVA Medical School, Universidade NOVA de Lisboa**.
- 2010 – 2013: Invited Lab classes of **Molecular Diagnostics and Bionanotechnology** of the **Master Course in Molecular Genetics and Biomedicine**, FCT/UNL, **Universidade NOVA de Lisboa**.

### **PEDAGOGICAL PRODUCTION**

- 2024 – Present: Video workshops about Oncology and AI for **Digital Data Design Institute at Harvard**, collaboration **Harvard Business School** and **NOVA Medical School**.

### **MEMBER**

- April 2024 – Present: Member of the **Lisbon Academy of Sciences**, Portugal.
- March 2020 – Present: Senior Member of the **Global Burden Disease (GBD)** consortium, **Institute for Health Metrics and Evaluation (IHME)**, University of Washington (US).


### **MENTORING EXPERIENCE**

- Jordi Martinez-Esain, **Marie Curie Fellow**, Nova Medical School (Apr 2025-to present).
- Jiemin Wang, **Marie Curie Fellow**, Nova Medical School (Apr 2025-to present).
- Beatriz Matos, **MSc student**, Nova Medical School and FCT-NOVA (Jan 2025-to present).
- Bruna Franco, **MSc student**, Nova Medical School, Gulbenkian Institute for Molecular Medicine and Instituto Superior Técnico (Feb 2025-Nov 2025).
- Joana Coutinho, **MSc student**, Nova Medical School and Instituto Politécnico de Setubal (Jan 2025-Dec 2025).
- Rita Rafael, **MSc student**, Nova Medical School (Sept 2024-Nov 2025).
- Emily Rohrmoser, **MSc student**, Nova Medical School (Sept 2024-Sept 2025).
- Diogo Dias, **BSc student**, Nova Medical School (Jan 2024-Sept 2024).
- Leonardo di Filippo, **PhD student**, School Pharmaceutical Sciences/UNESP (Jan 2023-Ago 2024).
- Alazne Moreno, **PhD student**, University of Barcelona (Sept 2023-Jan 2024).
- Cristina Volpini, **Erasmus student**, University of Pavia (Jan 2023-Sept 2023).
- Alessia Privitera, **Erasmus student**, University of Pavia (Jan 2023-Sept 2023).
- Marta Santos, **MSc student**, Nova Medical School and FCT-NOVA (Sept 2022-Sept 2023).
- Mariana Pereira, **MSc student**, Nova Medical School and Universidade do Algarve (Sept 2022-Sept 2023).
- Pedro Ribeiro, **PhD student**, Nova Medical School (Sept 2022-to present).
- Catarina Martins, **PhD student**, Nova Medical School and CIC biomaGUNE (Sept 2022-to present).
- João Pais, **PhD student**, Universidade de Coimbra and Nova Medical School (Sept 2022-to present).
- Ana Cunha, **BSc student**, Nova Medical School (Mar 2022-Jul 2022).
- Carolina Melo, **MSc student**, Faculdade Medicina, Universidade de Coimbra (Mar 2022-Jul 2022).
- Pedro Rosado, **BSc student**, Nova Medical School (Mar 2022-Apr 2022).
- Beatriz Salvado, **BSc student**, Nova Medical School (Feb 2022-Mar 2022).
- Ana Rita Mariano, **BSc student**, Nova Medical School (Feb 2022-Mar 2022).
- Jhenifer Oliveira, **PhD student**, Nova Medical School (Oct 2021-to present).
- Diana Castro Peixoto, **PhD student**, Universidade de Coimbra & Nova Medical School (Sept 2021-to present).

- Joana Amorim, **MSc student**, Nova Medical School (Sept 2021-Oct 2022).
- Diana Sousa, **PhD student**, Nova Medical School (Sept 2020-to present).
- Charlotte Baker, **PhD student**, Instituto de Medicina Molecular (Oct 2017-Oct 2019).
- Daniel Fulop, **MSc student**, Harvard University, Sophomore Internship (Jun 2015-Feb 2016).
- Cristina Violi, **MSc student**, Socrates-Erasmus Programme Italy, (Feb 2013-Aug 2013).
- André Salvada, **BSc student**, Universidade Nova de Lisboa, (Jan 2013-Mar 2013).
- Pedro Dionisio, **BSc student**, Universidade Nova de Lisboa, (Mar 2011-Sept 2011).

### **INTERNATIONAL NETWORKING/COLLABORATORS**

• Main collaborators: **Massachusetts Institute of Technology (US), Yale University (US), Harvard Medical School (US), Harvard University (US), Broad Institute of MIT and Harvard (US), Brigham and Women's Hospital (US), University of Washington (US), Dana-Farber Cancer Institute (US), Duke University (US), University of Pennsylvania (US), Tel Aviv University (Israel), University of British Columbia (Canada), Johns Hopkins University (US), Case Western Reserve University (US), University of Cambridge (UK), University of Oxford (UK), University College London (UK), University of Turin (IT), University Hospital Düsseldorf (Germany), Dublin Institute of Technology (Ireland), Shanghai JiaoTong University (China), University of Glasgow (UK), Fundação Champalimaud (Portugal), iMed.UL (Portugal), Universidade Coimbra (Portugal), among others.**



### **RESEARCH EVALUATOR**

- European Research Executive Agency, Brussels, Belgium.
- European Research Council, Brussels, Belgium.
- European Commission and Innovative Health Initiative (IHI), Brussels, Belgium.
- The Swiss National Science Foundation, Switzerland.
- August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.

- Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Portugal.
- Kingdom of Saudi Arabia Ministry of National Guard – Health Affairs, Saudi Arabia.

### **INSTITUTIONAL PROJECTS AS SCIENTIFIC COORDINATOR**

- LISBOA2030-FEDER-01317200 – Preclinical-to Clinical Innovation Hub for Nova Medical School (2025-2027). Coordinator. *Funding 3.2M€*
- Haddad Nova Medical Innovation Center – The Haddad Foundation (2025-2029). Co-coordinator. *Funding 3.25M€*

### **RESEARCH PROJECTS AS PI**

- FCT Grant LISBOA2030-FEDER-00862500-14998 – OncoNanoAI: Artificial intelligence to discover the next generation of personalized nanoparticles for triple-negative breast cancer therapy (2025-2027). *Funding 250K€*
- European Research Council – ERC Starting Grant: ERC-StG-2019-848325 – *GelGeneCircuit*: Profiling therapy and heterogeneity in cancer using bioresponsive nanohydrogels for the delivery of logic multicolor genetic circuits (2019-2025). *Funding 1.5M€*
- FCT Grant PTDC/BTM-MAT/4738/2020 – Biomimetic cell membrane-coated vitamin E-based micelles for multimodal pancreatic cancer nanotheranostics (2020-2023). *Funding 250K€*
- FCT Stimulus of Scientific Employment CEECIND/01688/2017 – Hydrogel scaffolds for delivery of gene therapies (2018-2019). *Funding 230K€*

### **RESEARCH PROJECTS with INDUSTRY**

- GENERA: A revolutionary, highly versatile drug delivery platform based on Metal-Organic Frameworks. By *Vector Bioscience Cambridge, Astrazeneca and Nova Medical School* - European Innovation Council – EIC Transition Grant (2023-2026). *Funding 2.5M€*

### **RESEARCH PROJECTS AS TEAM MEMBER or CONSULTANTS**

- BRIDGE: Breast cancer 3D models of Resistance in Drug Evaluation through Genomic and Epigenetic analysis. *FCT Grant, 2024.17625.PEX (2025-2027)*.
- BECAME: BrEast Cancer MicroEnvironment-mimetic platform for Evaluating personalized anticancer agents. *Liga Portuguesa contra o Cancro grant, 2022.07775.PTDC (2025-2027)*.
- SYN3D: Exploring the role of biomechanical forces in synapse formation as a strategy to combat neurodegeneration. *FCT Grant, LISBOA2030-FEDER-16494-SYN3D (2025-2027, as consultant)*.
- Specific RANK pathway inhibition for breast cancer-targeted therapy. *FCT Grant, LISBOA2030-FEDER-00677700-15681 (2025-2027)*.
- Innovative signaling inhibition in breast cancer using folate-targeted lipid nanoparticles. *Gilead GÉNESE, 26592 (2025-2027)*.
- PAIR-Lung: Patient-derived lung cancer organoids for recreating tumor spread through AIR spaces phenomenon. *FCT Grant, 2022.07775.PTDC (2022-2024)*.
- Combined immUNotherapeutiC approach for targeting bone marrow microenvironment in Multiple Myeloma. *FCT Grant, PTDC/MED-ONC/1215/2021 (2021-2024)*.

- Albumedix Ltd. - Recombinant albumin conjugates for cancer therapy (2018).
- SuprHAPolymers - Engineering self-assembly of hyaluronan-based glycopolymers with peptides (2016).
- NOF Corporation - Characterization of PEG-based hydrogels (2014-2015).
- NANOTRUCK- Multifunctional gold nanoparticles for gene therapy. *EU, ERANET-NanoSciera<sup>+</sup>* (2012-2014).
- Silence is golden (siAu) - Silencing the silencers via multifunctional gold nanoconjugates towards cancer therapy. *FCT Grant, FFCT/FCT/UNL, PTDC/BBB-NAN/1812/2012.*
- Nanosystems for delivery of caged compounds. *FCT Grant, FFCT/FCT/UNL, PTDC/QUI-QUI/112597/2009.*
- Sensitive and selective detection of DNA/RNA based on functionalized gold nanoparticles - application to pathogen detection, mutation detection and RNA quantification. *FCT Grant, FFCT/FCT/UNL, PTDC/BIO/66514/2006.*

### **START-UP COMPANIES**

- 2019 – Present: Co-founder and shareholder of *TargTex SA*, Portuguese start-up: Targeted therapies for the treatment of brain cancer. ***Portugal Ventures Funding 2M€ + Private Funding, Basi 2M€ + EIC Accelerator 14M€.*** João Conde is not employed by the company and does not hold an executive or operational role. He contributed substantially to the hydrogel-based therapeutic concepts that supported the scientific genesis of the company.

### **PRIZES AND AWARDS**

- 2024 - **Basinnov Innovation Award 2024** (honourable mention).
- 2024 - **Bluepharma Innovation Award 2023** (honourable mention).
- 2023 - **World's Top 2% Scientists list**, Stanford University.
- 2022 - **World's Top 2% Scientists list**, Stanford University.
- 2021 - **Nanomaterials 2020 Young Investigator Award.**
- 2021 - **Top 2% Most Cited Researchers in Nanoscience and Nanotechnologies**, PLOS Biology.
- 2021 - **2021 Biomaterials Science Emerging Investigators**, Royal Society of Chemistry.
- 2019 - **ERC Starting Grant:** ERC-StG-2019-848325, European Research Council, EU.
- 2018 - **Junior Investigator:** FCT Stimulus of Scientific Employment, (CEECIND/01688/2017) National Science Foundation, PT.
- 2017 - **Wellcome Image Awards 2017:** Wellcome Trust, UK.
- 2016 - **Nano-Micro Letters Researcher Award**, Nature Research Society.
- 2016 - **National Cancer Institute Image award:** Cancer close up, US.
- 2013 - **Marie Curie International Outgoing Fellowship** for Career Development, Marie Skłodowska-Curie actions (FP7-PEOPLE-2013-IOF).
- 2009 - **PhD Fellowship** - National Science Foundation - PhD Grant (FCT, SFRH/BD/62957/2009), PT.

## **PATENTS**

Inventor on **12 patent families in the field of nanomedicine**, covering technologies such as TRPV2 antagonists, nanoparticles for targeted therapy, microRNA delivery systems, and smart biomaterials. **A total of 27 patent applications submitted**, with **8 patents granted** across various jurisdictions (USA, Europe, Japan, Australia, among others). Ownership and licensing of patents are governed by the applicable institutional agreements.

1. Theranostic Nanoprobes for Overcoming Cancer Multidrug Resistance and Methods. U.S. Application No. 62/118101. MIT Case No. 17685K, MIT Docket No. 17685.117921.
2. RNA Triple Helix Structures, Compositions, and Methods. U.S. Application No. 62/216969. MIT Case No. 18323 PCT, MIT Docket No. 17648-0205.
3. Hydrogel particles, compositions, and methods. U.S. Application No. 62/339434.
4. Micro-RNA delivery compositions, devices, and methods. U.S. Application No. 62/353622.
5. Functionalized nanoparticles and compositions for cancer treatment and methods. U.S. Application No. 62/334538.
6. Hydrogel particle of cystamine cross-linked dextran aldehyde containing imine conjugated doxorubicin and RGD peptide for chemotherapy. U.S. Application No. PCT/US2017/033542.
7. TRPV2 Antagonists. WO EP CN JP AU BR CA EA SG Application No. PCT/PT2018/050035.
8. TRPV2 Antagonists. U.S. Application No. US11273152B2.
9. Metal-organic framework nanoparticles and hydrogels and uses thereof, PCT/EP2024/085805, 11/12/2024 (pending, Licensed).
10. Surfactant-based cellulose hydrogel methods and uses thereof, PCT/IB2025/051694, 17/02/2025, (pending).
11. Self-immolative micelle, methods and uses thereof, EP25165757, 24/03/2025 (pending).
12. Intranasal delivery for brain cancer and uses thereof (submitted).

## **JOURNAL EDITOR**

- **Editorial Board**, ACS Nano Medicine (2026 - to present).
- **Guest Editor**, Carbohydrate Polymers, Elsevier (2025 - to present).
- **Editorial Board**, Open Nano, Elsevier (2025 - to present).
- **Editorial Board**, ACS Chemical & Biomedical Imaging (2024 - to present).
- **Editorial Board**, Exploration, Wiley (2023 - to present).
- **Editorial Board**, Frontiers in Chemistry (2022 - to present).
- **Editorial Board**, VIEW, Wiley (2021 - to present).
- **Review Editor**, Frontiers Genetics - Toxicogenomics (2021 - to present).
- **Book editor**, "Handbook of Nanomaterials for Cancer Theranostics" by Elsevier (2017 - to present).
- **Volume Editor**, in the Advanced Nanomaterials Series, Elsevier (2016 - to present).
- **Editorial Board**, Nano Biomedicine and Engineering Journal (2016 - to present).
- **Associate Editor**, Frontiers in Bioengineering and Biotechnology (2015 - to present).
- **Associate Editor**, Frontiers in Molecular Biosciences (2015 - to present).
- **Associate Editor**, Frontiers in Materials (2015 - to present).
- **Guest Associate Editor**, Frontiers in Chemistry (2014 - to present).

## **JOURNAL REVIEWER**

- Nature Reviews Cancer; Nature Materials; Nature Cancer; Lancet Oncology; Nature Biotechnology; Nature Communications; Nature Protocols; Nature Reviews Bioengineering; PNAS; Accounts

Chemical Research; Chemical Reviews; Advanced Drug Delivery Reviews; Progress Polymer Science; Advanced Materials; ACS Nano; Advanced Functional Materials; Nature Asia Materials; Chemical Science; Theranostics; Small; Journal Controlled Release; Nanoscale; Analytical Chemistry; Advanced Healthcare Materials; Scientific Reports; Nanomedicine; Nanotoxicology; Nanomedicine: NBM; Acta Biomaterialia; Journal Materials Chemistry B; PLoS ONE; ACS Applied Materials & Interfaces; Bioconjugate Chemistry; Journal Biomedical Nanotechnology; Sensors & Actuators: B Chemical; Advanced Science; Nanoscale Research Letters; Colloids and Surfaces B: Biointerfaces; Journal of Nanobiotechnology; among others.

**Web of Science Review Metrics:** <https://www.webofscience.com/wos/author/record/1246512>

## **PUBLICATIONS**

- More than **180 articles** in high impact journals in fields of Nanomedicine, Oncology and Cancer Therapies and Biomedicine (*Nature* **IF50.5**, *Science* **IF45.8**, *The Lancet* **IF202.7**, *Nature Medicine* **IF50.0**, *Nature Materials* **IF43.8**, *Nature Reviews Materials* **IF76.7**, *The Lancet Oncology* **IF54.4**, *Nature Nanotechnology* **IF39.2**, *Chemical Society Reviews* **IF46.2**, *JAMA Oncology* **IF31.8**, *The Lancet Gastroenterology & Hepatology* **IF45.0**, *Science Advances* **IF12.5**, *Nature Communications* **IF14.9**, *The Lancet Child & Adolescent Health* **IF37.7**, *Military Medical Research* **IF34.9**, *The Lancet Public Health* **IF25.4**, *PNAS* **IF11.2**, *Accounts of Chemical Research* **IF22.4**, *Progress in Materials Science* **IF39.6**, *Advanced Materials* **IF30.8**, *Materials Today* **IF26.4**, *Nano Today* **IF16.9**, *ACS Nano* **IF15.9**, *JACS* **IF15.4**, *Angewandte Chemie* **IF15.3**, *Advanced Functional Materials* **IF18.8**, *Advanced Science* **IF17.5**, *Advanced Drug Delivery Reviews* **IF13.3**, *ACS Central Science* **IF14.5**, *Trends in Cancer* **IF14.2**, *Trends in Biotechnology* **IF19.5**, *Matter* **IF15.6**, *Biomaterials* **IF12.5**, *The Lancet Child & Adolescent Health* **IF11.3**, *Journal of Controlled Release* **IF7.9**, *Biosensors & Bioelectronics* **IF10.6**, *Nature Asia Materials* **IF10.5**).

- More than **30 articles as 1<sup>st</sup> author**, and more than **85 articles as corresponding author**, all cited **>33000 – h-index 71, Google Scholar; >27000 – h-index 64, Scopus**.

- Nearly **45** of them have been selected as **cover page of top-tier journals** such as *The Lancet*, *Nature Nanotechnology* (Covid-19 Special Issue), *The Lancet Oncology*, *Nature Materials*, *Trends in Cancer*, *Nature Reviews Materials*, *The Lancet Neurology*, *Advanced Materials*, *JAMA Oncology*, *ACS Nano*, *The Lancet Child & Adolescent Health*, *JACC*, *ACS Central Science*, *The Lancet Public Health*, *Adv. Functional Materials*, *JACS*, *Angewandte Chemie*, *ACS Sensors*, *WIREs Nanomedicine & Nanobiotechnology*, *Biomaterials Science*, *ACS Applied Bio Mat*, *Adv. Healthcare Materials*, *Analytical and Bioanalytical Chemistry* and *BioTechniques*.

## **PUBLICATIONS** (+85 articles as \* corresponding author)

**(180+ publications, Citations: >33000 h-index 71, Google Scholar; >27000 h-index 64, Scopus)**

1. “Wearable near-infrared LED photothermal microneedle patches reduce periorbital wrinkles in a randomized pilot clinical trial” Hyo-Won Han, D-H. Lee, A. Joe, Y.J. Jeon, Y-R. Lim, J. Choi, S.B. Lee, B-H. Bin, T. Thambi, **João Conde\***, P. Manivasagan\* and E-S. Jang\*. *Journal of Materials Chemistry B* (2026)
2. “Leading by listening: When I stopped trying to have all the answers, my lab members thrived”. **João Conde\***. *Science* (2026).

3. “A general strategy for site-oriented protein anchoring on metal-organic frameworks: HER2-targeted delivery using an engineered antibody fragment”. E. Siouve, F. Melle, Catarina F. Martins, C. Orozco, Jhenifer Oliveira, X. Chen, F. Demir-Duman, N. Ayaz, A. Madathil, K. Caamaño, Diana Peixoto, C. Camur, Bárbara B. Mendes, M. Bersellini, M. Carl, M. Papworth, P. Ravn, **João Conde\*** and D. Fairen-Jimenez\*. *ChemRxiv* (2026).
4. “European funder must increase capacity to meet the ambition of scientists”. **João Conde\***. *Nature* (2026).
5. “Procyanidin C1 activates Nrf2/HO-1 to preserve in vivo mitochondrial homeostasis and counter chondrocyte senescence in osteoarthritis”. Y. Zhang, M. Chen, W. Cai, Y. Zhou, J. Kuang, Y. Zhong, S. Wei, H. Xing, J. Zhou\*, **João Conde\***, Y. Zhou\*, H. Peng\* and W. Jin\*. *Cell Death & Disease* (2026). *Just accepted*
6. “One-pot synthesis of Mn/Fe bimetal-doped MOF as multifunctional nanocarriers for esophageal cancer targeted therapy”. J. Ma, X. Zhang, X. Meng, Y. Dai, H. Wang, M. Ashrafizadeh, **João Conde\***, Z. Li\*, E. Yao\* and W. He\*. *Journal of Pharmaceutical Analysis* (2026). *Just accepted*
7. “Mitochondrial Flagella-like Extensions (MitoFLARE) dysfunction triggers STING-mediated immune dysregulation in sepsis”. W. Hong, R. Ma, S. Long, R. Song, S. Ren, X. Ran, J. Wan, Y. Liu, X. Li, Q. Chen, D. Ma, Z. Zhang, H. Huang, M. Ashrafizadeh, **João Conde\***, L. Liu\* and C. Duan\*. *Nature Communications* (2026).
8. “Clinical Large Language Model Centered On Electronic Medical Records”. Y. Zhuang, B. Wang, C. Yin, J. Zhang, F. Meng, J. Zhao, Q. Su, X. Zhao, X. Li, P. Hu, Wurilige, Y. Hua, W. Dong, B. Wei, L. Zheng, **João Conde\***, G. Shi\*, C. Feng\* and K. He\*. *npj Digital Medicine* (2026). *Just accepted*
9. “Microvesicle release drive cycles of mitophagy flux disruption and inflammatory amplification in sepsis-induced myocardial dysfunction”. R. Song, Y. Ma, J. Wan, S. Hao, B. Chen, Y. Liao, Y. Liao, Y. Xiao, X. Zhang, Z. Zhang, S. Ren, X. Tan, J. Tan, H. Huang, **João Conde\***, G. Sethi, L. Liu\* and C. Duan\*. *PNAS* (2026).
10. “DNA/RNA hybrid hairpin gold nanobeacons targeting miR-31 reprogram invasion in lung cancer and remodel tumor histo-architecture in vivo”. Diana P. Sousa, Jhenifer Oliveira, Catarina F. Martins and **João Conde\***. *ACS Materials Au* (2026).
11. “NFYB-lncRNA axis resets the tumor microenvironment to promote HCC aggressive progression by a positive feedback loop”. B. Zhou, Q. Tao, W. Wen, J. Tan, J. Xu, Y. Fang, J. Guan, X. Lin, J. He, M. Ashrafizadeh, Z. Wang\*, **João Conde\*** and F. Zheng\*. *Acta Pharmaceutica Sinica B* (2026).
12. “Global burden of adverse effects of medical treatment from 1990 to 2021: a Global Burden of Disease Study 2021”. **João Conde** and GBD Collaborators - Global Burden of Disease (GBD) Consortium. *The Korean Journal of Internal Medicine* (2026).
13. “A predictive rheological framework to define printability of thermo-sensitive bioinks using non-temperature-controlled bioprinters”. I. Anjos, T. Vieira, T. Aktar, J.C. Silva, Barbara B. Mendes, **João Conde**, L.F. Bolaños, S. Fernandes, C. Leal, J.P. Borges and D. Limón\*. *Polymer Testing* (2026).
14. “SIRT3 deficiency impairs mitochondrial bioenergetics via hyperacetylation of TCA cycle enzymes in chronic heart failure”. Y. Liao, X. Tan, G. Peng, Y. Ren, R. Liu, H. Liao, Z. Luo, Z. Cao, Y. Wu, M. Ashrafizadeh, **João Conde\***, C. Duan\*, J. Hu\* and R. Ma\*. *Journal of Translational Medicine* (2026).
15. “Cytoskeletal remodeling promotes tunneling nanotube formation and drives cardiac resident cell mitochondrial transfer in sepsis”. R. Song, C. Huang, Y. Ma, Z. Zhang, Y. Liu, B. Chen, X.

- Zhang, S. Hao, H. Huang, M. Ashrafizadeh, **João Conde\*** and C. Duan\*. *Science Advances* (2026).
16. “Mapping Burdens and Inequalities of Polycystic Ovary Syndrome in Young Female across 953 Locations 1990 to 2040 with Deep Learning Forecasts”. **João Conde** and GBD Collaborators - Global Burden of Disease (GBD) Consortium. *iScience* (2026).
  17. “Macrophage membrane-cloaked, ROS-triggered quercetin nanocarriers target ovarian lesions to treat polycystic ovary syndrome”. W. Li, Y. Guan, N. Song, F. Zhang, Z. Deng, T. Yin, Y. Yang\*, **João Conde\***, W. Jin\* and Z. Yin\*. *Advanced Healthcare Materials* (2026).
  18. “Smart multifunctional hydrogels with shape memory, conductivity, self-healing and adhesive properties for biomedical applications”. H. Huong, C.H. Luu, V.H. Giang Phan, G. Janarthanan, N-T. Huynh, H.T. Nguyen, N-Y.N. Ha, H.T. Ta, S. Vijayavenkataraman\*, **João Conde\*** and T. Thambi\*. *Materials & Design* (2026).
  19. “Global, regional, and national burden of breast cancer among females, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023”. **João Conde** and GBD Collaborators - Global Burden of Disease (GBD) Consortium. *The Lancet Oncology* (2026).
  20. “A reproducible workflow for macrophage membrane isolation and nanocore selection toward bioinspired nanoparticles targeting immunologically cold tumors”. Diana Peixoto, P. Diaz-Rodriguez, F. Veiga, A. Concheiro, A.C. Paiva-Santos, **João Conde\*** and C. Alvarez-Lorenzo\*. *Small Methods* (2026).
  21. “Advancements and challenges in CAR-NK cell therapy for cancer treatment”. Z. Xu, Y. Zhou, J. Kuang, Y. Li, C. Ye, H. Guo\*, C. Yin\*, **João Conde\*** and S. Liu\*. *Trends in Biotechnology* (2026).
  22. “Global to local burdens, inequalities, and achievable frontiers of child and adolescent malignant neoplasm of bone and articular cartilage across 953 countries and sublocations, 1980-2040, with deep learning-based forecasts”. **João Conde** and GBD Collaborators - Global Burden of Disease (GBD) Consortium. *Journal of Orthopaedic Translation* (2026).
  23. “Global, regional, and national burden of chronic respiratory diseases and impact of the COVID-19 pandemic, 1990-2023: a Global Burden of Disease study”. **João Conde** and GBD Collaborators - Global Burden of Disease (GBD) Consortium. *Nature Medicine* (2026).
  24. “Advancements and challenges in CAR-NK cell therapy for cancer treatment”. Z. Xu, Y. Zhou, J. Kuang, Y. Li, C. Ye, H. Guo\*, C. Yin\*, **João Conde\***, S. Liu\*. *Trends in Cancer* (2025).
  25. “Structurally and functionally optimized silk fibroin-alginate-based biomimetic scaffolds reinforced with nanobioceramics for bone tissue engineering applications”. T-M.N. Nguyen, N-H.H. Le, M. Murugesan, G. Janarthanan, P. Manivasagan, E-S. Jang, Y. Li, V.H.G. Phana, S. Vijayavenkataraman\*, **João Conde\*** and T. Thambi\*. *Journal of Nanobiotechnology* (2025).
  26. “Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023”. **João Conde** and GBD Collaborators - Global Burden of Disease (GBD) Consortium. *The Lancet* (2025).
  27. “Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950–2023”. **João Conde** and GBD Collaborators - Global Burden of Disease (GBD) Consortium. *The Lancet* (2025).
  28. “Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990–2023”. **João Conde** and GBD Collaborators - Global Burden of Disease (GBD) Consortium. *The Lancet* (2025).

29. “The global, regional, and national burden of cancer, 1990–2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2021”. **João Conde** and GBD Collaborators - Global Burden of Disease (GBD) Consortium. *The Lancet* (2025).
30. “Macrophage efferocytosis mediated by the TP63–RAC2 pathway promotes immunosuppressive remodeling in esophageal cancer”. Y. Xi, Z. Xu, Z. Zhao, Y. Zhou, C. Yin, W. Jin, C. Lin, J. Kuang, B. Yu\*, **João Conde\***, S. Liu\* and W. Shen\*. *Cell Reports Medicine* (2025).
31. “Global, Regional and National Burden of Cardiovascular Diseases and Risk Factors in 204 countries and territories, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023”. **João Conde** and GBD Collaborators - Global Burden of Disease (GBD) Consortium. *Journal of the American College of Cardiology* (2025).
32. “Accelerating discoveries in cancer nanomedicine using AI”. C. Guan, Bárbara B. Mendes, João Coniot, A.L. Dias, L. Hammad, T. Thambi, R. Langer\*, T. Rodrigues\*, **João Conde\*** and C. de la Fuente-Nunez\*. *Cell Biomaterials* (2025).
33. “A tumor microenvironment-responsive Zr-MOF nanosystem for co-delivering siHIF-1 $\alpha$  and triptolide enhances photodynamic therapy in esophageal cancer by amplifying ROS generation and reversing hypoxia”. W. Liu, C. Sun, Y. Dai, H. Wang, M. Ashrafizadeh, **João Conde\***, L. Yang\* and W. Hea\*. *Materials Today Bio* (2025).
34. “Nanoscale analysis beyond imaging by atomic force microscopy: molecular perspectives on oncology and neurodegeneration”. C. Marcuello\*, K. Lim, G.Nisini, V.S. Pokrovsky, **João Conde\*** and F.S. Ruggeri\*. *Small Science* (2025).
35. “Multiscale profiling of nanoscale metal-organic framework immune interactions”. Y. Zhuang, Bárbara B. Mendes, D. Menon, Jhenifer Oliveira, X. Chen, F.D. Duman, João Coniot, S. Mercado, X. Liu, S. Zhang, J.J. Powell, **João Conde\***, R.E. Hewitt\* and D. Fairen-Jimenez\*. *Advanced Healthcare Materials* (2025).
36. “Conductive polymers in smart wound healing: from bioelectric stimulation to regenerative therapies”. Y. Jiang, Y. Zhou, Y. Tian, N. Nabavi, M. Ashrafizadeh, **João Conde\***, Z. Li\* and L. Guo\*. *Materials Today Bio* (2025).
37. “How to de-Americanise global science”. **João Conde\***. *Nature* (2025).
38. “Tumor immunotherapy targeting immune cell mitochondria”. H. Li, W. Jin, J. Liu, Y. Zhou, X. Shan, Y. Zhang, Y. Kou, C. Deng, C. Jin, Y-L. Lau\*, B. Huang\*, **João Conde\***, J. Kuang\* and Q. Lin. *Trends in Cancer* (2025).
39. “Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: a systematic analysis for the Global Burden of Disease Study 2023”. **João Conde & GBD Consortium**. *The Lancet* (2025).
40. “Bridging the innovation gap and rethinking translation in biomaterials Science”. Bárbara B. Mendes\*, R. Prasad\* and **João Conde\***. *Matter (Cell Press)* (2025).
41. “Characterising acute and chronic care needs: insights from the Global Burden of Disease Study 2019”. **João Conde & GBD Consortium**. *Nature Communications* (2025).
42. “Folic acid-targeted macrophage membrane-coated carbon quantum dot nanoplatfor for dual drug and gene delivery in metastatic osteosarcoma therapy”. E. Yao, Y. Li, K. Deng, W. He\*, M. Ashrafizadeh, **João Conde\*** and L. Yang\*. *Chemical Engineering Journal* (2025).
43. “ANXA1 mRNA-loaded bio-liposomes alleviate acute pancreatitis by suppressing STING pathway via promoting efferocytosis in macrophages”. H. Fang, P. You, Y. Wu, F. Liang, C. Chen, Z. Hou, Z. Wang, J. Lin, L. Chen, S. Zhang, X. Chen, F. Lu, **João Conde\***, H. Huang\* and Y. Pan\*. *Nature Nanotechnology* (2025).

44. “Bioengineered metastatic cancer nanovaccine with a TLR7/8 agonist for needle-free intranasal immunization”. J.M. Jung, M.S. Lee, Y.K. Seo, J.E. Lee, S.Y. Lim, D.H. Kim, S.Y. Lyu, C. Park, B.D. Kim, J.H. Shin, J.H. Lee, P. Liu, J. Jung, **João Conde**, T. Thambi, J.H. Jeong and D.S. Lee. *Biomaterials* (2025).
45. “Zn-DHM nanozymes enhance muscle regeneration through ROS scavenging and macrophage polarization in volumetric muscle loss revealed by single-cell profiling”. X. Feng, Z. Luo, W. Zhang, R. Wan, Y. Chen, F. Li, Y. He, Z. Lin, J.H. Hui, Y. Li, **João Conde\***, S. Chen\*, Z. Zhao\*, X. Wang\*. *Advanced Functional Materials* (2025).
46. “Longan-inspired chitosan-pectin core-shell hydrogel beads for oral delivery of biodrugs to enhance osteoporosis therapy”. V.H.G. Phan, B-P. T. Nguyen, N.Y. Nguyen, C-N. D. Tran, Q-N. D. Nguyen, C.H. Luu, P. Manivasagan, E-S Jang, D.C. Yang, D.U. Yang, Y. Li\*, **João Conde\*** and T. Thambi\*. *International Journal of Biological Macromolecules*. (2025).
47. “Aging-associated reduction in ER-mitochondrial contacts impairs mitochondrial lipid metabolism and autophagosome formation in the heart”. W. Hong, X. Zeng, R. Ma, Y. Tian, H. Miu, X. Ran, R. Song, Z. Luo, D. Ju, D. Ma, M. Ashrafizadeh, S.K. Bhutia, **João Conde**, G. Sethi\*, H. Huang\* and C. Duan\*. *Cell Death & Differentiation* (2025).
48. “Enzyme-responsive vitamin D-based micelles for paclitaxel controlled delivery in pancreatic cancer therapy”. Diana Peixoto, João M. Ravasco, B. Blanco-Fernández, F. Veiga, A. Concheiro, **João Conde\***, A.C. Paiva-Santos\* and C. Alvarez-Lorenzo\*. *Materials Today Bio* (2025).
49. “Age-sex-specific burden of urological cancers attributable to risk factors in China and its provinces, 1990–2021, and forecasts with scenarios simulation”. M. Xue, W. Guo, Y. Zhou, J. Meng, Y. Xi, L. Pan, Y. Ye, Y. Zeng, Z. Che, L. Zhang, P. Ye, **João Conde\***, Q. Lin\*, Wenyi Jin\*. *The Lancet Regional Health - Western Pacific* (2025).
50. “Long-term cell-membrane coated ultrabright polymeric nano-dots for targeted cancer cell imaging and hydrophobic drug delivery”. Rajendra Prasad\*, N. Gupta, A.S. Meena, V.G.S.S. Jyothi, A. Chan-dak and **João Conde\***. *Chemistry of Materials* (2025). Featured on COVER
51. “Changing life expectancy in European countries 1990-2021: causes and risk factors from the Global Burden of Disease Study 2021”. **João Conde & GBD Consortium**. *The Lancet Public Health* (2025).
52. “Advancing nanomedicine from lab to clinic through personalized approaches and collaborative innovation”. **João Conde\***. *Cell Reports Physical Science* (2025).
53. “Exploring the link between low germline mutational load and low breast cancer incidence: lessons from the Xavante Indians”. José Rueff\*, **João Conde\*** and Guilherme Castro\*. *Translational Oncology* (2025).
54. “Rational design of Metal-Organic Frameworks for pancreatic cancer therapy: from machine learning screening to *in vivo* efficacy”. F. Melle, D. Menon, João Connot, J. Ostolaza-Paraiso, X. Chen, S. Mercado, Jhenifer Oliveira, Bárbara B. Mendes, **João Conde\*** and D. Fairen-Jimenez\*. *Advanced Materials* (2025).
55. “Engineered biomimetic cisplatin-polyphenol nanocomplex for chemo-immunotherapy of glioblastoma by inducing pyroptosis”. X. Hao, Y. Tang, W. Xu, M. Wang, J. Liu, Y. Li, J. He, Y. Peng, P. Sun, D. Liao, X. Hu, T. Tang, M. Zhou, R. Han, J. Wang, **João Conde\***, D. Xiang\* and J. Wu\*. *Journal of Nanobiotechnology* (2025).
56. “Voices of Nanomedicine: blueprint guidelines for collaboration in addressing global unmet medical needs”. R. Prasad\*, A. Ghosh, V. Patel, B. Peng, Bárbara B. Mendes, E.H.A. Win, L.G. Delogu, J.Y. Wong, K.J. Pische, J. Bellare, A. Bar-Shir, A.S. Thakor, W.J. Parak, Z.M. Bhujwalla, Y.S. Zhang, N. Kommineni, V. Rotello, W. Cai, T. Lammers, T.W. Odom, G. Padmanaban, D.

- Peer, J.F. Lovell, R. Srivastava\*, R. Langer and **João Conde\***. *ACS Nano* (2025). Featured on COVER
57. “The burden of diseases, injuries, and risk factors by state in the USA, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021”. **João Conde & GBD Consortium.** *The Lancet* (2024). Featured on COVER
58. “Burden of disease scenarios by state in the USA, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021”. **João Conde & GBD Consortium.** *The Lancet* (2024). Featured on COVER
59. “Nano-navigated macrophages: Piercing liver inflammation, fibrosis, and cancer”. A. Moreno-Lanceta, E.R. Edelman, **João Conde\***, P Melgar-Lesmes\*. *Matter (Cell Press)* (2024)
60. “Forecasting the effects of smoking prevalence scenarios on years of life lost and life expectancy from 2022 to 2050: a systematic analysis for the Global Burden of Disease Study 2021”. **João Conde & GBD Consortium.** *The Lancet Public Health* (2024). Featured on COVER
61. “Triterpenoid saponin-based supramolecular host-guest injectable hydrogels inhibit the growth of melanoma via ROS-mediated apoptosis” R. Mathiyalagan, M. Murugesan, Z.M. Ramadhania, J. Nahar, P. Manivasagan, E-S. Jang, D.C. Yang, **João Conde\*** and T. Thambi\*. *Materials Science and Engineering: R: Reports* (2024).
62. “The power of nanobot technology in cancer treatment” B.B. Mendes and **João Conde\***, *Matter (Cell Press)* (2024). Featured on COVER
63. “Electric Field-Responsive Gold Nanoantennas for the Induction of a Locoregional Tumor pH Change Using Electrolytic Ablation Therapy” Joe A, Manivasagan P, Park JK, Han HW, Seo SH, Thambi T, Giang Phan VH, Kang SA, **João Conde\***, Jang ES\*. *ACS Nano* (2024). Featured on COVER
64. “Biomimetic Ghost Nanomedicine-Based Optotheranostics for Cancer”. R. Prasad\*, V.G.S.S. Jyothi, N. Kommineni, R.T Bulusu, B.B. Mendes and **João Conde\***. *Nano Letters* (2024). Featured on COVER
65. “The state of health in the European Union (EU-27) in 2019: A systematic analysis for the Global Burden of Disease Study 2019” **João Conde & GBD Consortium.** *BMC Public Health* (2024).
66. “Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021” **João Conde & GBD Consortium.** *The Lancet* (2024).
67. “Engineered nanomaterials for glioblastoma nanovaccination” F. Haamedat, Barbara Mendes, João Coniot, L.D. Di Filippo, M. Chorilli, A. Petri-Fink, A. Schroeder, **João Conde\***, F. Sousa\*. *Nature Reviews Materials* (2024).
68. “Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021” **João Conde & GBD Consortium.** *The Lancet* (2024).
69. “Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021” **João Conde & GBD Consortium.** *The Lancet* (2024). Featured on COVER
70. “Enhancing selectivity and overcoming tissue-specific toxicity in drug discovery: A novel BET inhibitor with targeted delivery for prostate cancer treatment” R. Traquete, E. Henderson, **João Conde**, S. Picaud, C. Tang, P. Filippakopoulos\* and G.J.L. Bernardes\*. *Cancer Research* (2024).

71. “Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021” **João Conde & GBD Consortium**. *The Lancet* (2024). Featured on COVER
72. “Progress in nanomaterial-based synergistic photothermal-enhanced chemodynamic therapy in combating bacterial infections” P. Manivasagan, T. Thambi, A. Joe, H-W. Han, S-H. Seo, Y.J. Jeon, **João Conde\***, E-S. Jang\*. *Progress in Materials Science* (2024).
73. “Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021” **João Conde & GBD Consortium**. *The Lancet* (2024). Featured on COVER
74. “A large-scale machine learning analysis of inorganic nanoparticles in preclinical cancer research”. Bárbara B. Mendes, Z. Zhang, João Coniot, Diana P. Sousa, João M.J.M. Ravasco, L. Onweller, A. Lorenc, T. Rodrigues\*, D. Reker\* and **João Conde\***. *Nature Nanotechnology* (2024).
75. “Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021” **João Conde & GBD Consortium**. *The Lancet Neurology* (2024). Featured on COVER
76. “Preclinical assessment of an antibiotic-free cationic surfactant-based hydrogel for sexually and perinatal transmitted infections”. R.D.A. Calado, Bárbara B. Mendes, João Coniot, João M.J.M. Ravasco, D. Sobral, C. Ferreira, R. Ferreira, J.C. Rodrigues, D. Santos, S. Duarte, L. Vieira, A.S. Inácio, H. Carrêlo, W.L.C. Vaz, J.P. Gomes, A. Nunes\*, **João Conde\*** and O.V. Vieira\*. *Matter (Cell Press)* (2024).
77. “Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021” **João Conde & GBD Consortium**. *The Lancet* (2024). Featured on COVER
78. “Biomimetic bright optotheranostics for metastasis monitoring and multimodal image-guided breast cancer therapeutics”. R. Prasad\*, B. Peng, Bárbara B. Mendes, H.I. Kilian, M. Gorain, H. Zhang, G.C. Kundu, J. Xia, J.F. Lovell and **João Conde\***. *Journal of Controlled Release* (2024).
79. “Hydrogel microneedles: a theranostic toolbox for personalized nanomedicine”. Catarina F. Martins, C. García-Astrain, **João Conde** and L. Liz-Marzán\*. *Drug Delivery and Translational Research* - Special Issue in honor of Prof. Patrick Couvreur (2024).
80. “A fluorinated BODIPY-based zirconium metal-organic framework for *in vivo* enhanced photodynamic therapy”. X. Chen, Bárbara B. Mendes, Y. Zhuang, João Coniot, S.M. Argandona, F. Melle, Diana P. Sousa, D. Perl, A. Chivu, H. K. Patra, W. Shepard, **João Conde\*** and D. Fairen-Jimenez\*. *Journal American Chemical Society* (2024).
81. “Cathepsin B processing is required for the *in vivo* efficacy of albumin-drug conjugates”. B. Bernardim, **João Conde**, T. Hakala, J.B. Becher, M. Canzano, A.V. Vasco, T.P.J. Knowles, J. Cameron and G.J.L. Bernardes\*. *Bioconjugate Chemistry* - ACS Editors' Choice (2024).
82. “Global Burden of Cardiovascular Diseases and Risks, 1990-2022”. **João Conde & GBD Consortium**. *Journal of the American College of Cardiology* (2023).
83. “Bioinspired and biomimetic cancer cell-membrane derived nanovesicles for preclinical tumor-targeted nanotheranostics”. Rajendra Prasad\*, Bárbara B. Mendes, M. Gorain, G.C. Kundu, N. Gupta, B. Peng, E.H.A. Win, Q. He and **João Conde\***. *Cell Reports Physical Science* (2023).

84. “Passive Nanoparticles for Organ-Selective Systemic Delivery: Design, Mechanism and Perspective”. L. Fu, Y. Zhang, R.A. Farokhzad, Bárbara B. Mendes, **João Conde** and J. Shi\* *Chemical Society Reviews* (2023).
85. “Intratumoural Delivery of mRNA Loaded on a Cationic Hyper-Branched Cyclodextrin-Based Polymer Induced an Anti-Tumour Immunological Response in Melanoma”. F. Trotta, M. Mahmoudian, P. Zakeri-Milani, C. Cecone, K.J. Ishii, T. Hayashi, **João Conde**, A. Matencio and Y.K. Monfared. *Cancers* (2023).
86. “Conjugated Nanoparticles for Solid Tumor Theranostics: Unraveling the Interplay of Known and Unknown Factors”. V.P. Chavda, P.C. Balar, L.V. Nalla, R. Bezbaruah, N.R. Gogoi, S.N.R. Gajula, B. Peng, A.S. Meena, **João Conde**, R. Prasad\*. *ACS Omega* (2023)
87. “Evolution of CRISPR-enabled biosensors for amplification-free nucleic acid detection”. Sepehr Talebian\*, Fariba Dehghani, Paul S. Weiss and **João Conde\***. *Trends in Biotechnology* (2023)
88. “Highlight: Biomimetic hydrogel supporting baths as an alternative to initiate and maintain breast tumor-derived organoids culture”. J. Oliveira, M. Pereira, B. Mendes\* and **João Conde\***. *MedComm - Biomaterials and Applications* (2023).
89. “Engineered Liposomes in Interventional Theranostics of Solid Tumors”. N. Kommineni, R. Chaudhari, **João Conde**, S. Tamburaci, B. Cecen, P. Chandra, R. Prasad. *ACS Biomaterials Science & Engineering* (2023). Featured on COVER
90. “A Receptor-mediated Landscape of Druggable and Targeted Nanomaterials for Gliomas”. L.D.D Filippo, S.G. Carvalho, J.L. Duarte, M.T. Luiz, J.A.P. Dutra, G.A. Paula, M. Chorilli and **João Conde\***. *Materials Today Bio* (2023).
91. “Bioengineered exosome membrane camouflaged-abiotic nanocarriers: neurodegenerative diseases, tissue engineering and regenerative medicine”. D. Lopes, J. Lopes, M. Pereira-Silva, Diana Peixoto, F. Veiga, S. Yousefiasl, N. Rabiee, **João Conde**, P. Makvandi and A.C. Paiva-Santos. *Military Medical Research* (2023).
92. “Hydrogels for RNA Delivery”. R. Zhong, S. Talebian, Barbara Mendes, G. Wallace, R. Langer, **João Conde\*** and J. Shi\*. *Nature Materials* (2023). Featured on COVER
93. “mRNA therapy at the convergence of genetics and nanomedicine”. **João Conde\***, Robert Langer and José Rueff. *Nature Nanotechnology* (2023).
94. “Biopolymeric coatings for local release of therapeutics from biomedical implants”. S. Talebian, Bárbara Mendes, João Coniot, S. Farajikhah, F. Dehghani, Z. Li, D. Bitoque, G. Silva, S. Naficy, **João Conde\*** and G.G. Wallace\*. *Advanced Science* (2023).
95. “Exosome Membrane-Coated Nanosystems: Exploring Biomedical Applications in Cancer Diagnosis and Therapy”. M. Shao, D. Lopes, J. Lopes, S. Yousefias, A. Macário-Soares, Diana Peixoto, I. Ferreira-Faria, F. Veiga, **João Conde**, Y. Huang, X. Chen, A.C. Paiva-Santos and P. Makvandi. *Matter, Cell Press* (2023).
96. “Technological challenges of biomembrane-coated top-down cancer nanotherapy”. João M.J.M. Ravasco, A.C. Paiva-Santos\* and **João Conde\***. *Nature Reviews Bioengineering* (2023).
97. “Using gold nanobeacons as a theranostic technique to recognize, detect, and inhibit specific nucleic acids”. Diana P. Sousa and **João Conde\***. *STAR Protocols, Cell Press* (2022).
98. “Magnetite and bismuth sulfide Janus heterostructures as radiosensitizers for in vivo enhanced radiotherapy in breast cancer”. H. Nosrati, M. Ghaffarlou, M. Salehiabar, N. Mousazadeh, F. Abhari, M. Barsbay, Y.N. Ertas, H. Rashidzadeh, A. Mohammadi, L. Nasehi, H. Rezaeejam, S. Davaran, A. Ramazani\*, **João Conde\*** and H. Danafar\*. *Biomaterials Advances* (2022).

99. “Nucleic acid-based therapy for brain cancer: Challenges and strategies”. Z. Zhang, João Conniot, Joana Amorim, Y. Jin, R. Prasad, X. Yan\*, K. Fan\* and **João Conde\***. *Journal of Controlled Release* (2022) - VSI: Brain Targeting Issue.
100. “Gold nanoconjugates for miRNA modulation in cancer therapy: from miRNA silencing to miRNA mimics”. Diana P. Sousa and **João Conde\***. *ACS Materials Au* (2022) - Rising Stars Issue & Editors’ choice. Featured on COVER
101. “The global burden of cancer attributable to risk factors, 2010–2019: a systematic analysis for the Global Burden of Disease Study 2019.” **João Conde & GBD Consortium.** *The Lancet* (2022).
102. “Macrophage cell membrane-cloaked nanoplatfoms in biomedical applications”. J. Lopes, D. Lopes, M. Pereira-Silva, D. Peixoto, F. Veiga, M.R. Hamblin, **João Conde**, C. Corbo, E.N. Zare, M. Ashrafizadeh, F.R. Tay, C. Chen, X. Wang, P. Makvandi and A.C. Santos. *Small Methods* (2022).
103. “Global, Regional and National Burden of Colorectal Cancer, 1990-2019: A systematic examination for Global Burden of Disease 2019”. **João Conde & GBD Consortium.** *The Lancet Gastroenterology & Hepatology* (2022).
104. “The burden of non-communicable diseases in adolescents in 28 European countries, 1990-2019: A Systematic Analysis of the Global Burden of Diseases, Injuries, and Risk Factors Study.” **João Conde & GBD Consortium.** *The Lancet Child & Adolescent Health* (2022). Featured on COVER
105. “Nano-delivery of nucleic acids”. Bárbara B. Mendes, João Conniot, A. Avital, D. Yao, X. Jiang, X. Zhou, O. Adir, Y. Xiao, N. Sharf-Pauker, H. Liang\*, J. Shi\*, A. Schroeder\* and **João Conde\***. *Nature Reviews Methods Primers* (2022).
106. “Bioinspired Soft Nanovesicles as Site-Selective Imaging and Targeted Therapies of Cancer”. Rajendra Prasad\*, **João Conde\*** to *WIREs Nanomedicine and Nanobiotechnology* (2022).
107. “Prodrug polymeric nanoconjugates encapsulating gold nanoparticles for enhanced X-Ray radiation therapy in breast cancer” H. Nosrati, F. Seidi, A. Hosseinmirzaei, N. Mousazadeh, A. Mohammadi, Mo. Ghaffarlou, H. Danafar, **João Conde\*** and Ali Sharafi\*. *Advanced Healthcare Materials - Rising Star Issue* (2021). Featured on COVER
108. “Controlled delivery of gold nanoparticle-coupled miRNA therapeutics via an injectable self-healing hydrogel”. C.F.T. van der Ven, M.W. Tibbitt, **João Conde**, A. van Mil, J. Hjortnaes, P.A.F.M. Doevendans, J.P.G. Sluijter, E. Aikawa and Robert Langer. *Nanoscale* (2021) - Featured on COVER
109. “The global burden of adolescent and young adult cancer in 2019: An analysis of the Global Burden of Disease Study 2019”. **João Conde & GBD Consortium.** *The Lancet Oncology* (2021). Featured on COVER
110. “Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life Years for 29 Cancer Groups from 2010 to 2019: A Systematic Analysis of Cancer Burden Globally, Nationally, and by Socio-Demographic Index for the Global Burden of Disease Study 2019”. **João Conde & GBD Consortium.** *JAMA Oncology* (2021).
111. “Machine-readable Nanotechnology for future healthcare research”. Andzelika Lorenc, Bárbara B. Mendes, João Conniot, Diana P. Sousa, **João Conde\*** and Tiago Rodrigues\*. *Matter (Cell Press)* (2021).
112. “Global, regional, and national progress toward Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden

- of Disease Study 2019”. **João Conde & GBD Consortium**. *The Lancet* (2021). Featured on COVER
113. “Facts and Figures on Materials Science and Nanotechnology Progress and Investment”. S. Talebian, T. Rodrigues, J. das Neves, B. Sarmiento, R. Langer, **João Conde\***. *ACS Nano* (2021). Featured on COVER
114. “Nanotechnology-based strategies to target and modulate the tumor microenvironment”. Barbara Mendes, João Coniot, Diana Sousa, **João Conde\***. *Trends in Cancer* (2021). Featured on COVER.
115. “Allosteric Antagonist Modulation of TRPV2 by Piperlongumine Impairs Glioblastoma Progression”. **João Conde**, R.A. Pumroy, C. Baker, T. Rodrigues, A. Guerreiro, B.B. Sousa, M.C. Marques, B.P. de Almeida, S. Lee, E.P. Leites, D. Picard, A. Samanta, S.H. Vaz, F. Sieglitz, M. Langini, M. Remke, R. Roque, T. Weiss, M. Weller, Y. Liu, S. Han, F. Corzana, V.A. Morais, C.C. Faria, T. Carvalho, P. Filippakopoulos, B. Snijder, N.L. Barbosa-Morais, V.Y. Moiseenkova-Bell, G.J.L. Bernardes. *ACS Central Science* (2021) Featured on COVER.
116. “CRISPR Systems for COVID-19 Diagnosis” H. Rahimi, M. Salehiabar, M. Barsbay, M. Ghaffarlou, T. Kavetsky, A. Sharafi, S. Davaran, Subhash C. Chauhan, H. Danafar, S. Kaboli, H. Nosrati, M.M. Yallapu, and **João Conde\***. *ACS Sensors* (2021) Featured on COVER.
117. “Ultrahigh penetration and retention of graphene quantum dot mesoporous silica nanohybrids for image guided tumor regression”. R. Prasad\*, N.K. Jain, A.S. Yadav, M. Jadhav, N.N.V. Radharani, M. Gorain, G.C. Kundu, **João Conde\***, R. Srivastava\*. *ACS Applied Bio Materials* (2021) Featured on COVER.
118. “Osteogenic Differentiation of Human Mesenchymal Stem Cells by the Single Action of Luminescent Polyurea Oxide Biodendrimers”. Rita F. Pires, **João Conde\*** and Vasco D.B. Bonifacio\*. *ACS Applied Bio Materials* (2020).
119. “Revisiting Gene Delivery to the Brain: Silencing and Editing” (2021 Biomaterials Science Emerging Investigators Issue). João Coniot, Sepehr Talebian, Susana Simões, Lino Ferreira\*, **João Conde\***. *Biomaterials Science* (2020) Featured on COVER.
120. “Stepwise Assembly of Multimode Liposomal Nanotheranostic Agent for Targeted In Vivo Bioimaging and NIR Light Mediated Cancer Therapy”. R. Prasad, N.K. Jain, A.S. Yadav, D.S. Chauhan, J. Devrukhkar, M.K. Kumawat, S. Shinde, M. Gorain, A.S. Thakor, G.C. Kundu, **João Conde\***, R. Srivastava\*. *Communications Biology* (2020).
121. “Biomimetic cancer cell membrane coated-nanosystems as next-generation cancer therapies”. M. Pereira-Silva, A.C. Santos, **João Conde**, C. Hoskins, A. Concheiro, C. Alvarez-Lorenzo, F. Veiga. *Expert Opinion on Drug Delivery* (2020).
122. “Why Go NANO on COVID-19 pandemic?”. Sepehr Talebian and **João Conde\***. *Matter (Cell Press)* (2020).
123. “Nanotechnology-based disinfectants and sensors for SARS-CoV-2” S. Talebian, G.G. Wallace, A. Schroeder, F. Stellacci and **João Conde\***. *Nature Nanotechnology* (2020) COVID-19 Special Issue.
124. “Localized Nanotheranostics: Recent developments in Cancer Nanomedicine”. R. Prasad, N.K. Jain, **João Conde\***, R. Srivastava. *Materials Today Advances* (2020).
125. “Above and beyond Cancer Therapy: translating biomaterials into clinics” **João Conde\*** *Trends in Cancer* (2020).
126. “Tetrazine carbon nanotubes for pretargeted in vivo ‘click-to-release’ bioorthogonal imaging” H. Li, **João Conde**, A. Guerreiro, G.J.L. Bernardes. *Angewandte Chemie International Edition* (2020). VIP paper. Featured on COVER.

127. “Platinum-triggered Bond-cleavage of Pentynoyl amide and N-propargyl handles for Drug-Activation” B.L. Oliveira, B.J. Stenton, Unnikrishnan V.B., C.R. Almeida, **João Conde**, M. Negrão, F.S.S. Schneider, C. Cordeiro, M.G. Ferreira, G.F. Caramori, J.B Domingos, R. Fior and G.J.L. Bernardes. *Journal of the American Chemical Society* (2020). Featured on COVER.
128. “Prolonged Local In Vivo Delivery of Stimuli-Responsive Nanogels That Rapidly Release Doxorubicin in Triple-Negative Breast Cancer Cells”. Y. Zhang, P. Dosta, **João Conde**, N. Oliva, M. Wang and N. Artzi. *Advanced Healthcare Materials* (2020). Featured on COVER.
129. “Cisplatin-Triggered Bioorthogonal Decaging of Amide Bonds for Targeted-Drug Activation in vivo”. B. Stenton, B. Oliveira, **João Conde**, M. Negrão, M. Godinho Ferreira, R. Fior, G. Bernardes. *ChemRxiv. Preprint* (2019).
130. “Allosteric Antagonist Modulation of TRPV2 by Piperlongumine Impairs Glioblastoma Progression”. C. Baker, T. Rodrigues, R.A. Pumroy, **João Conde**, D. Picard, M.C. Marques, B.P. de Almeida, A. Samanta, F. Sieglitz, M. Langini, M. Remke, R. Roque, F. Corzana, C.C. Faria, T. Carvalho, N.L. Barbosa-Morais, V.Y. Moiseenkova-Bell, G.J.L. Bernardes. *Cell, Sneak Peek* (2019).
131. “Oral pH sensitive GNS@ab Nanoprobes for targeted therapy of Helicobacter Pylori without disturbance gut microbiome” X. Zhi, Y. Liu, L. Lin, M. Yang, L. Zhang, L. Zhang, Y. Liu, G. Alfranca, L. Ma, Q. Zhang, H. Fu, **João Conde**, X. Di, J. Ni, J. Song, D. Cui. *Nanomedicine: Nanotechnology, Biology and Medicine* (2019).
132. “Gastric parietal cell and Intestinal goblet cell secretion: a novel cell-mediated in vivo nanoparticle clearance pathway enhanced with diarrhea via Chinese Herbs”. Y. Liu, K. Liu, M. Yang, Y. Han, Q. Zhang, **João Conde**, Y. Yang, Y. Han, G. Alfranca, Y. Wang, J. Song, Y. Zhang, J. Ni, J.M. de la Fuente, D. Cui. *Nanoscale Research Letters* (2019).
133. “Biopolymers for anti-tumor implantable drug delivery systems: Recent advances and future outlook”. S. Talebian, S. Wadeb, J. Foroughi, K. L. Vineb, A. Dolatshahi-pirouz, M. Mehrali, **João Conde**, G. Wallace. *Advanced Materials* (2018).
134. “Ferritin nanocarrier traverses the blood brain barrier and kills glioma”. K. Fan, X. Jia, M. Zhou, **João Conde**, J. He, J. Tian, X. Yan. *ACS Nano* (2018).
135. “Nanoparticle-antagomiR based targeting of miR-31 to induce osterix and osteocalcin expression in mesenchymal stem cells”. M. McCully, **João Conde**, P.V. Baptista, M. Mullin, M.J. Dalby, C.C. Berry. *PLOS ONE* (2018).
136. “Plasmonic gold nanoparticles for detection of fungi and human cutaneous fungal infections” T. Sojinrin, **João Conde\***, K. Liu, J. Curtin, H.J. Byrne H, D. Cui, F. Tian\*. *Analytical and Bioanalytical Chemistry* (2017). Featured on COVER.
137. “Fullerene: Biomedical Engineers Get to Revisit an Old Friend” S. Goodarzi, T. Da Ros, **João Conde**, F. Sefat and M. Mozafari. *Materials Today* (2017).
138. “Designing Hydrogels for On-Demand Therapy” N. Oliva, **João Conde**, K. Wang and N. Artzi. *Accounts of Chemical Research* (2017).
139. Smart NIR linear and nonlinear optical nanomaterials for cancer theranostics: Prospects in photomedicine”. T.M. Liu, **João Conde\***, T. Lipiński, A. Bednarkiewicz and C-C. Huang. *Progress in Materials Science* (2017).
140. “Gold Nanostars for real-time intracellular and in vivo SERS detection combined with drug delivery via plasmonic-tunable Raman/FTIR imaging”. F. Tian, **João Conde\***, C. Bao, Y. Chen, J. Curtin and D. Cui. *Biomaterials* (2016).
141. “Revisiting the ‘one material fits all’ rule for cancer nanotherapy”. **João Conde\***, N. Oliva, N. Artzi\*. *Trends in Biotechnology* (2016).

142. “Biomaterials for Metastasis: Bridging the Gap between Basic and Translational Research” **João Conde**, N. Shomron and N. Artzi. *Advanced Healthcare Materials* (2016). VIP paper. Featured on COVER.
143. “Revisiting the classification of NIR absorbing/emitting Nanomaterials for in vivo bio-applications”. T-M. Liu, **João Conde\***, T. Lipinski, A. Bednarkiewicz, C-C. Huang. *Nature Asia Materials* (2016).
144. “3D hydrogel scaffold doped with 2D materials for biosensors and bioelectronics”. H.S. Song, O.S. Kwon, **João Conde\*** and N. Artzi. *Biosensors & Bioelectronics* (2016).
145. “Gold Nanoprisms as a hybrid in vivo Cancer Theranostic platform for in situ Photoacoustic Imaging, Angiography and localized Hyperthermia”. C. Bao, **João Conde**, F. Pan, C. Li, C. Zhang, F. Tian, S. Liang, J.M. de la Fuente and D. Cui. *Nano Research* (2016).
146. “Chiral Antioxidant-based Gold Nanoclusters Reprogram DNA Epigenetic Patterns”. Y. Ma, H. Fu, C. Zhang, S. Cheng, J. Gao, Z. Wang, W. Jin, **João Conde\*** and D. Cui. *Scientific Reports* (2016).
147. “Local triple-combination therapy results in tumour regression and prevents recurrence in a colon cancer model”. **João Conde\***, N. Oliva, Y. Zhang and N. Artzi. *Nature Materials* (2016). Highlighted in *Science Translational Medicine* and *Science Bulletin*.
148. “Local microRNA delivery targets Palladin and prevents metastatic breast cancer”. A. Gilam, **João Conde**, D. Weissglas-Volkov, N. Oliva, N. Artzi, N. Shomron. *Nature Communications* (2016).
149. “Self-assembled RNA-triple-helix hydrogel scaffold for microRNA modulation in the tumour microenvironment”. **João Conde\***, N. Oliva, M. Atilano, H.S. Song, N. Artzi. *Nature Materials* (2016). Highlighted in *Science Translational Medicine* and *The Scientist*.
150. “Dual-Color Emissive Upconversion Nanocapsules for Differential Cancer Bioimaging in vivo”. O.S. Kwon, H.S. Song, **João Conde**, H. Kim, N. Artzi and J.H. Kim. *ACS Nano* (2016).
151. “Implantable hydrogel embedded dark-gold nanoswitch as a theranostics probe to sense and overcome cancer multidrug resistance”. **João Conde\***, N. Oliva, N. Artzi. *PNAS* (2015). Highlighted in *Nature Reviews Drug Discovery*.
152. “Bioresponsive antisense DNA gold nanobeacons as a hybrid in vivo theranostics platform for the inhibition of cancer cells and metastasis”. C. Bao, **João Conde\***, J. Curtin, N. Artzi, F. Tian, D. Cui. *Scientific Reports* (2015).
153. “Personalizing biomaterials for precision nanomedicine in light of local tissue microenvironment”. N. Oliva, S. Unterman, Y. Zhang, **João Conde**, H.S. Song and N. Artzi. *Advanced Healthcare Materials* (2015). Featured on COVER.
154. “Dual targeted immunotherapy via in vivo delivery of bio-hybrid RNAi-peptide nanoparticles to tumour-associated macrophages and cancer cells”. **João Conde\***, C. Bao, Y. Tan, D. Cui, E.R. Edelman, H.S. Azevedo, H.J. Byrne, N. Artzi, F. Tian. *Advanced Functional Materials* (2015). VIP paper. Featured on COVER.
155. “RNAi nanomaterials targeting immune cells as an anti-tumor therapy: the missing link in cancer treatment? **João Conde\***, C. Arnold, F. Tian and N. Artzi. *Materials Today* (2015)
156. “The next generation of smart gold nanobeacons: nanotheranostics is ready for prime-time”. **João Conde\*** and N. Artzi. *Nanomedicine (Lond.)* (2015).
157. “Are RNAi and miRNA therapeutics truly dead?”. **João Conde\***, N. Artzi. *Trends in Biotechnology* (2015).

158. “Target-Responsive DNA/RNA nanomaterials for microRNA sensing and inhibition: the jack-of-all-trades in cancer nanotheranostics?”. **João Conde\***, E.R. Edelman, N. Artzi. *Advanced Drug Delivery Reviews* (2015).
159. “15 years on siRNA delivery: beyond the State-of-the-Art on inorganic nanoparticles for RNAi therapeutics”. **João Conde\***, A. Ambrosone, Y. Hernandez, F. Tian, M. McCully, C.C. Berry, P.V. Baptista, C. Tortiglione, J.M. de la Fuente. *Nano Today* (2015).
160. “Editorial: Cancer Nanotheranostics - What have we learned so far?”. **João Conde\***, F. Tian, J.M. de la Fuente, P.V. Baptista. *Frontiers in Chemistry* (2015).
161. “The Golden Age in Cancer Nanobiotechnology: Quo vadis?”. **João Conde\***. *Frontiers in Bioengineering and Biotechnology* (2015).
162. “RNAi-based glyconanoparticles trigger apoptotic pathways for in vitro and in vivo enhanced cancer-cell killing”. **João Conde**, F. Tian, Y. Hernandez, C. Bao, P.V. Baptista, D. Cui, T. Stoöger and J.M. de la Fuente. *Nanoscale* (2015).
163. “Significance of the balance between intracellular glutathione and polyethylene glycol for successful release of small interfering RNA from gold nanoparticles” M. McCully, Y. Hernandez, **João Conde**, P.V. Baptista, J.M. de la Fuente, A. Hursthouse, D. Stirling and C.C. Berry. *Nano Research* (2015).
164. “Gold Nanoparticle-siRNA Mediated Oncogene Knockdown at RNA and Protein level, with associated Gene effects” H.W. Child, Y. Hernandez, **João Conde**, M. Mullin, P.V. Baptista, J.M. de la Fuente and C.C. Berry. *Nanomedicine (Lond.)* (2015).
165. “Investigating the role of shape on the biological impact of gold nanoparticles in vitro” F. Tian, M.J.D. Clift, A. Casey, P. del Pino, B. Pelaz, **João Conde**, H.J. Byrne, B. Rothen-Rutishauser, G. Estrada, J.M. de la Fuente and T. Stoeger. *Nanomedicine (Lond.)* (2015).
166. “POxylated polyurea dendrimers: Smart core-shell vectors with IC50 lowering capacity”. R.B. Restani, **João Conde**, R.F. Pires, P. Martins, A.R. Fernandes, P.V. Baptista, V.D.B. Bonifácio and A. Aguiar-Ricardo. *Macromolecular Bioscience* (2015).
167. “Polyurea dendrimer for efficient cytosolic siRNA delivery” R.B. Restani, **João Conde**, P.V. Baptista, M.T. Cidade, A.M. Bragança, J. Morgado, I.J. Correia, A. Aguiar-Ricardo and V.D.B. Bonifácio. *RSC Advances* (2014).
168. “A promising road with challenges: where gold nanoparticles are in translational research?” C. Bao, **João Conde**, E. Polo, P. del Pino, M. Moros, P.V. Baptista, V. Grazu, D. Cui and J.M. de la Fuente. *Nanomedicine (Lond.)* (2014).
169. “Antibody-Drug gold nanoantennas with Raman spectroscopic fingerprints for in vivo tumour theranostics.” **João Conde\***, C. Bao, D. Cui, P. Baptista, F. Tian. *Journal of Controlled Release* (2014).
170. “Revisiting 30 years of Biofunctionalization and Surface Chemistry of Inorganic Nanoparticles for Nanomedicine.” **João Conde\***, J.T Dias, V. Grazú, M. Moros, P.V. Baptista, Jesús M. de la Fuente. *Frontiers in Chemistry* (2014).
171. “A Gold-nanobeacon system for Gene therapy: evaluation of Genotoxicity, Cell toxicity and Proteome profiling analysis” **João Conde**, M. Larguinho, A. Cordeiro, L.R. Raposo, P.M. Costa, S. Santos, M.S. Diniz, A.R. Fernandes and P.V. Baptista. *Nanotoxicology* (2014).
172. “In vivo tumour targeting via nanoparticle-mediated therapeutic siRNA coupled to inflammatory response in lung cancer mouse models.” **João Conde**, F. Tian, Y. Hernández, C. Bao, D. Cui, K.P. Janssene, M.R. Ibarra, P.V. Baptista, T. Stoöger and J.M. de la Fuente. *Biomaterials* (2013).

173. “Gold-Nanobeacons as a theranostic system for the detection and inhibition of specific genes”. **João Conde**, J. Rosa and P.V. Baptista. *Nature Protocol Exchange* (2013).
174. “Nanomaterials for reversion of multidrug resistance in cancer: a new hope for an old idea?” **João Conde\***, J.M. de la Fuente, P.V. Baptista. *Frontiers in Pharmacology* (2013).
175. “Gold-Nanobeacons for simultaneous gene specific silencing and intracellular tracking of the silencing events.” **João Conde**, J. Rosa, J.M. de la Fuente and P.V. Baptista. *Biomaterials* (2013).
176. “Design of Multifunctional Gold Nanoparticles for in vitro and in vivo Gene Silencing.” **João Conde**, A. Ambrosone, V. Sanz, Y. Hernández, V. Marchesano, F. Tian, H. Child, C.C. Berry, M.R. Ibarra, P.V. Baptista, C. Tortiglione and J.M. de la Fuente. *ACS Nano* (2012).
177. “Effect of PEG biofunctional spacers and TAT peptide on dsRNA loading on Gold Nanoparticles”. V. Sanz, **João Conde**, Y. Hernández, P.V. Baptista, M.R. Ibarra and J.M. de la Fuente. *Journal of Nanoparticle Research* (2012).
178. “Modification of Plasmid DNA Topology by Histone-Mimetic Gold Nanoparticles”. **João Conde**, P.V. Baptista, Y. Hernández, V. Sanz and J.M. de la Fuente. *Nanomedicine (Lond.)* (2012).
179. “Gold-Nanobeacons for Real-Time Monitoring of RNA Synthesis”. J. Rosa, **João Conde**, J.M. de la Fuente, J.C. Lima and P.V. Baptista. *Biosensors & Bioelectronics* (2012).
180. “Noble Metal Nanoparticles for Biosensing Applications” G. Doria, **João Conde**, B. Veigas, L. Giestas, C. Almeida, M. Assunção, J. Rosa and P.V. Baptista. *Sensors (Basel)* (2012).
181. “Noble Metal Nanoparticles Applications in Cancer” **João Conde**, G. Doria and P.V. Baptista. *Journal of Drug Delivery* (2012).
182. “Nanophotonics for Molecular Diagnostics and Therapy Applications” **João Conde**, J. Rosa, J.C. Lima and P.V. Baptista. *International Journal Photoenergy* (2012).
183. “Genotoxic effects of occupational exposure to lead and influence of polymorphisms in genes involved in lead toxicokinetics and in DNA repair”. J. García-Lestón, J. Roma-Torres, M. Vílars, R. Pinto, J. Prista, J.P. Teixeira, O. Mayan, **João Conde**, M. Pingarilho, J.F. Gaspar, E. Pásaro, J. Méndez and B. Laffon. *Environment International* (2012).
184. “Alloy Metal Nanoparticles for Multicolour Cancer Diagnostics”. P.V. Baptista, G. Doria and **João Conde**. *Proceedings of SPIE* (2011).
185. “In vitro Transcription and Translation Inhibition via DNA functionalized Gold Nanoparticles” **João Conde**, J.M. de la Fuente and P.V. Baptista. *Nanotechnology* (2010).
186. “Use of Cyclodextrins as Scavengers of Inhibitory Photo-products in Light controlled in vitro Synthesis of RNA”. A. Vidal Pinheiro, **João Conde**, A.J. Parola, J.C. Lima and P.V. Baptista. *Journal of Photochemistry and Photobiology A: Chemistry* (2010).
187. “RNA Quantification using Gold Nanoprobes - application to Cancer Diagnostics”. **João Conde**, J.M. de la Fuente and P.V. Baptista. *Journal of Nanobiotechnology* (2010).
188. “Association of common variants in Mismatch Repair Genes and Breast Cancer susceptibility: a Multigene study”. **João Conde**, S.N. Silva, A.P. Azevedo, V. Teixeira, J.E. Pina, J. Rueff and J.F. Gaspar. *BMC Cancer* (2009).

#### **BOOKs and BOOK CHAPTERS** (\* corresponding author)

1. “Unveiling MicroRNA Biomarkers for Breast Cancer Sub-typing Using Discriminative Models” 1<sup>st</sup> Edition, J. Mota, J. Romano, A.R. Grosso, **João Conde**, Bárbara Mendes and D. Semedo. *in EPIA Conference on Artificial Intelligence, Springer, 2025.*

2. “Handbook of Nanomaterials for Cancer Theranostics” 1<sup>st</sup> Edition, *Editor: **João Conde***, Elsevier, 2018.
3. “Displaying biofunctionality on materials through templated self-assembly”, K. Shuturminska, C. O'Malley, D.W.P. Collis, **João Conde**, H.S. Azevedo, *in Self-Assembling Biomaterials: Molecular Design, Characterization and Application in Biology and Medicine, Elsevier*, 2018.
4. “Empowering the potential of cell-penetrating peptides for targeted intracellular delivery via molecular self-assembly”, Y. Shi, **João Conde**, H.S. Azevedo, *in Peptides and Peptide-based Biomaterials and their Biomedical Applications*, Eds. A. Sunna, A. Care, P. Bergquist, *Springer International Publishing AG*, Cham, 2017.
5. “Multifunctional Gold Nanocarriers for Cancer Theranostics – From bench to bedside and back again?” **João Conde\***, F. Tian, P.V. Baptista., J.M. de la Fuente. *in Nano-Oncologicals: New Targeting and Delivery Approaches (2014), Springer Science+Business Media. Controlled Release Society*.
6. “RNA Quantification Using Noble Metal Nanoprobes: Simultaneous Identification of Several Different mRNA Targets Using Colour Multiplexing and Application to Cancer Diagnostics.” **João Conde**, G. Doria, J.M. de la Fuente and P.V. Baptista\*. *in Nanoparticles in Biology and Medicine: Methods and Protocols Series (2012). Humana Press, Springer Protocols*.

### **CONFERENCE & SEMINAR PRESENTATIONS**

- Speaker at Commemorations of the 25<sup>th</sup> anniversary of Escola Superior de Saúde do Instituto Politécnico de Setúbal (ESS/IPS), in association with collaborations in the Bachelor’s Degree in Biomedical Technology and the Master’s Degree in Biomedical Engineering, March 2025, Portugal (*Invited*).
- Roundtable Chair at Cascais International Health Forum by Forum Saude XXI, March 2025, Portugal (*Invited*).
- Speaker at Jornadas Biológicas, Instituto Superior de Psicologia Aplicada (ISPA), February 2025, Portugal (*Invited*).
- Roundtable Chair at 2<sup>nd</sup> Oncological Urology Conference – Present and Future, Hospital CUF Tejo, January 2025, Portugal (*Invited*).
- Global Hybrid Summit 2024 – Real World Evidence for the Real World, November 2024, Portugal (*Invited*).
- Speaker at the Meeting USP/NOVA on Artificial Intelligence, Health and Precision Medicine, June 2024, São Paulo, Brazil (*Invited*).
- Speaker at the Leading with AI: Exploring Business and Technology Frontiers – Harvard Business School and Nova SBE, April 2024, Portugal (*Invited*).
- Speaker at the 19<sup>th</sup> European Molecular Imaging Meeting, March 2024, Portugal (*Invited*).
- Health Innovation - From Ideas to Impact: How Health Professionals, Patients and Carers Contribute to Technological Advances in Health, NOVA Medical School and NOVA School of Business and Economics, September 2023, Portugal (*Invited*).
- Keynote Speaker at the Liga Portuguesa contra o Cancro, September 2023, Portugal (*Invited*).
- Speaker at the Sustainable Value Creation Summit (SVCS) “How to Create Value using basic/fundamental science”, Nova SBE, May 2023, Portugal (*Invited*).
- Roundtable titled mRNA: The next revolution, Science|Business and Moderna, April 2023, Brussels, Belgium (*Invited*).

- Nanomedicine Seminar Series – “Working on the landscape of Precision Nanomedicine in Oncology” – Houston Methodist Research Institute, Houston Methodist Hospital, March 2023, Houston, USA (*Invited*).
- VIII Semana da Bioengenharia – Keynote Speaker – “It’s nano or never: The importance of nanotechnologies in the healthcare future”, Instituto Superior Técnico (IST), March 2023, Portugal (*Invited*).
- ITQB PhD Program 2022 - MolBioS Doctoral Program: Nanoprocess for Life Science, March 2022, Portugal (*Invited*).
- “Application of multifunctional nano-and-biomaterials for cancer therapy and diagnosis” - Master Program in Biopharmaceutical Sciences, Oncobiology, FFUL, February 2022, Portugal (*Invited*).
- BioMedicine and BioSciences Seminar Series - University of Bergen (UiB), February 2022, Norway (*Invited*).
- Roundtable Chair on careers in the biomedical sciences, The Non-Conformist Scientist and the National Association of Biomedical Engineering Students, January 2022, Boston (*Invited*).
- “TIPS for applying to CEEC 5th edition 2022?” - Lyris, Advanced Science Education, January 2022 (*Invited*).
- Biotech in Action S2: Water Cooler Talk - Massachusetts Institute of Technology (MIT), Harvard–MIT Division for Health Sciences and Technology, July 2021, Boston, Massachusetts, USA (*Invited*).
- “The story behind my path in Cancer NanoMedicine” at the PostDoc ShowCase 2<sup>nd</sup> edition - Department of Pharmacy, University of Naples Federico II, June 2021, Italy (*Invited*).
- 9<sup>th</sup> Session IST- MedNetworking – To see or not to see: How Nanotechnology is redefining Medicine, Instituto Superior Técnico (IST), May 2021, Portugal (*Invited*).
- JorTec 2021 - Jornadas Tecnológicas (JorTec) da Faculdade de Ciências e Tecnologia, February 2021, Portugal (*Invited*).
- Keynote Speaker - 13<sup>o</sup> Encontro Nacional de Química Orgânica/6<sup>o</sup> Encontro Nacional de Química Terapêutica (13ENQO/6ENQT), January 2020, Portugal (*Invited*).
- Seminar, March 2017, University of Glasgow, Institute of Molecular Cell and Systems Biology, Glasgow, Scotland (*Invited*).
- Nanomedicine Seminars, February 2017, Trinity College Dublin, School of Medicine, Dublin, Ireland (*Invited*).
- 10<sup>th</sup> World Biomaterials Congress, May 2016, Montreal, Canada.
- 11<sup>th</sup> Annual Broad Retreat - Broad Institute of MIT and Harvard, December 2015, Boston, Massachusetts, USA.
- Society for Biomaterials 2015, April 2015, North Carolina, USA.
- 4<sup>th</sup> International Conference on Multifunctional, Hybrid and Nanomaterials, March 2015, Barcelona, Spain.
- 8<sup>th</sup> International Conference of Coelenterate Biology, December 2013, North Beach, Eilat, Israel.
- Collaborative Congress of the European Society for Gene and Cell Therapy and the Spanish Society for Gene and Cell Therapy, October 2013, Madrid, Spain.
- International Conference on Materials for Advanced Technologies 2013. Symposium R: Ecological and Health Impact of Nanomaterials and Nanotechnology, July 2013, Singapore.
- European Conference of Human Genetics 2013, June 2013, Paris, France.
- E-MRS 2013 SPRING MEETING, Bionanomaterials for imaging, sensing and actuating, May 2013, Strasbourg, France.

- Elsevier 3<sup>rd</sup> International Conference on Multifunctional, Hybrid and Nanomaterials (Hybrid Materials 2013), March 2013, Sorrento, Italy.
- Materials Research Society Fall Meeting, November 2012, Boston, Massachusetts, USA.
- NanoMed2012, International Conference on Nanotechnology in Medicine, November 2012, University College London, London, UK.
- American Chemical Society Spring 2012 National Meeting, March 2012, San Diego, California, USA.
- Miami 2012 Winter Symposium: Nanotechnology in Biomedicine, February 2012, Miami, USA.
- SPIE West 2012, San Francisco, USA.
- SPIE West 2011, Colloidal Quantum Dots/Nanocrystals for Biomedical Applications VI, February 2011, San Francisco, USA.
- TNT2010 – Trends in Nanotechnology, September 2010, Braga, Portugal.
- National Congress MicroBiotec'09, 2009, Vilamoura, Portugal.
- EURONANOFORUM 2009. Nanotechnology for Sustainable Economy. European and International Forum on Nanotechnology, June 2009, Prague, Czech Republic.
- XXXIV Genetic Journeys - Human Cancer Genetics and Genotoxicity, Portuguese Society of Human Genetics, 2009, Lisbon, Portugal.

## **COMMUNITY OUTREACH**

- May 2026 – *Science* article (Working Life article): “Listening and empowering changed the way I lead: the leadership lesson I didn’t learn in the lab”. <https://www.science.org/content/article/when-i-stopped-trying-have-all-answers-my-lab-members-thrived>
- May 2026 – *Nature* article (World View article): “Europe mustn’t sabotage its scientific future through funding weakness”. <https://www.nature.com/articles/d41586-026-01411-0>
- May 2026 – *Expresso* article: “O novo RJIES: a universidade entre a repartição e o triunfo das capelinhas”. <https://expresso.pt/opiniao/2026-05-05-o-novo-regime-juridico-a-universidade-entre-a-reparticao-e-o-triunfo-das-capelinhas-ead21cca>
- Mar 2026 – *Times Higher Education* article: “Is striving for excellence a liability for Europe’s early-career precariat?”. <https://www.timeshighereducation.com/depth/striving-excellence-liability-europes-early-career-precariat>
- Mar 2026 – *Expresso* article: “AI<sup>2</sup>: uma reforma que começou pelo fim e se esconde num labirinto metodológico”. <https://expresso.pt/opiniao/2026-03-23-ai2-uma-reforma-que-comecou-pelo-fim-e-se-esconde-num-labirinto-metodologico-47a02bae-1>
- Jan 2026 – *Observador* article: “Quando os dados clínicos não alimentam a investigação nem chegam à cama do doente: a (outra) crise silenciosa do SNS”. <https://observador.pt/opiniao/quando-os-dados-clinicos-nao-alimentam-a-investigacao-nem-chegam-a-cama-do-doente-a-outra-crise-silenciosa-do-sns/>
- Dec 2025 – *Expresso* article: “O cientista na era do assistente incansável: quando a IA força a redesenhar a carreira científica”. <https://expresso.pt/opiniao/2025-12-08-o-cientista-na-era-do-assistente-incansavel-quando-a-ia-forca-a-redesenhar-a-carreira-cientifica-ea20762d>

- Oct 2025 – *Observador* article: “Outubro rosa, um apelo claro a todos nós: celebrar quem partiu, cuidar de quem fica”. <https://observador.pt/opiniao/outubro-rosa-um-apelo-claro-a-todos-nos-celebrar-quem-partiu-cuidar-de-quem-fica/>
- Sep 2025 – *Expresso* article: “Plano Marshall para a Ciência: como Portugal pode construir em 5 anos o que andou 25 a adiar”. <https://expresso.pt/opiniao/2025-09-17-plano-marshall-para-a-ciencia-como-portugal-pode-construir-em-5-anos-o-que-andou-25-a-adiar-9d65b713>
- Aug 2025 – *Público* article: “O paradoxo da extinção da FCT que nos dá mais reforma do Estado e menos ciência”. <https://www.publico.pt/2025/08/21/ciencia/opiniao/paradoxo-extincao-fct-reforma-estado-menos-ciencia-2143832>
- Jul 2025 – *Nature* article (World View article): “How to de-Americanize global science”. <https://www.nature.com/articles/d41586-025-02215-4>
- Jul 2025 – *Expresso* article: “Cativações recorde e dívidas malparadas: como a FCT se tornou o travão invisível da investigação”. <https://expresso.pt/opiniao/2025-07-29-cativacoes-recorde-e-dividas-malparadas-como-a-fct-se-tornou-o-travao-invisivel-da-investigacao-8b2b576c>
- Jun 2025 – *Público* article: “Entre bolsas e promessas, a reforma que falta à Ciência em Portugal”. <https://www.publico.pt/2025/06/21/ciencia/opiniao/bolsas-promessas-reforma-falta-ciencia-portugal-2136865>
- Jun 2025 – *Sábado* article: “Cancro: Os novos avanços da medicina”. <https://www.sabado.pt/ciencia---saude/detalhe/cancro-os-novos-avancos-da-medicina>
- May 2025 – *Expresso* article: “Pode a ciência transformar Portugal sem indústria? E pode a indústria fazer Portugal evoluir sem investigação?”. <https://expresso.pt/opiniao/2025-05-21-pode-a-ciencia-transformar-portugal-sem-industria--e-pode-a-industria-fazer-portugal-evoluir-sem-investigacao--e017d857>
- Apr 2025 – *Público* article: “NOVA Medical School recebe 3,25 milhões para criar ecossistema colaborativo”. <https://www.publico.pt/2025/04/16/estudiop/noticia/nova-medical-school-recebe-325-milhoes-criar-ecossistema-colaborativo-2129835>
- Mar 2025 – *Expresso* article: “Medicina 4.0 – como a inteligência artificial está a revolucionar a formação dos médicos do futuro”. <https://expresso.pt/opiniao/2025-03-20-medicina-4.0-como-a-inteligencia-artificial-esta-a-revolucionar-a-formacao-dos-medicos-do-futuro-ee25a44c>
- Jan 2025 – *Expresso* article: “Ciência e saúde em mudança: o que significam as novas políticas dos EUA?”. <https://expresso.pt/opiniao/2025-01-30-ciencia-e-saude-em-mudanca-o-que-significam-as-novas-politicas-dos-eua--7bd96c3d>
- Dec 2024 – *Observador* article: “O desafio da precariedade em Portugal: construir um futuro para a investigação”. <https://observador.pt/opiniao/o-desafio-da-precariedade-em-portugal-construir-um-futuro-para-a-investigacao/>
- Feb 2022 – *Público* article: Hidrogel de pimenta pode ajudar a eliminar tumor cerebral”. <https://www.publico.pt/2022/02/13/ciencia/noticia/hidrogel-pimenta-ajudar-eliminar-tumor-cerebral-1995197>
- Feb 2022 – *Público* article: “Mortes por cancro subiram 20% no mundo numa década. Em Portugal foi 10%”. <https://www.publico.pt/2022/02/04/sociedade/noticia/mortes-cancro-subiram-20-mundo-decada-portugal-10-1993975>

- Ago 2021 – *Diário de Notícias* article: “Na quimioterapia só 5% a 10% do fármaco chega ao local. Na nanotecnologia não há dispersão, é mais eficaz e menos tóxico”. <https://www.dn.pt/edicao-do-dia/26-ago-2021/na-quimioterapia-so-5-a-10-do-farmaco-chega-ao-local-na-nanotecnologia-nao-ha-dispersao-e-mais-eficaz-e-menos-toxico-14061636.html>
- Sep 2019 – *Publico* article: “Cancro da mama e fake news trazem 2,9 milhões de euros de bolsas europeias”. <https://www.publico.pt/2019/09/03/ciencia/noticia/cancro-mama-fake-news-trazem-29-milhoes-euros-bolsas-europeias-1885325>
- Sep 2019 – *Expresso* article: “Estudos portugueses sobre fake news e sobre terapia do cancro da mama ganham bolsas milionárias do Conselho Europeu de Investigação”. <https://expresso.pt/sociedade/2019-09-03-Estudos-portugueses-sobre-fake-news-e-sobre-terapia-do-cancro-da-mama-ganham-bolsas-milionarias-do-Conselho-Europeu-de-Investigacao>
- Sep 2019 – *RTP Noticias* article: “Um milhão de euros para pesquisa portuguesa de novas terapias do cancro de mama”. [https://www.rtp.pt/noticias/pais/um-milhao-de-euros-para-pesquisa-portuguesa-de-novas-terapias-do-cancro-de-mama\\_v1170897](https://www.rtp.pt/noticias/pais/um-milhao-de-euros-para-pesquisa-portuguesa-de-novas-terapias-do-cancro-de-mama_v1170897)
- Sep 2016 – *MIT News* article: “Gene therapy technique may help prevent cancer metastasis”. <https://news.mit.edu/2016/gene-therapy-technique-prevent-cancer-metastasis-0919>
- Jul 2016 – *MIT News* article: “Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results”. <https://news.mit.edu/2016/patch-delivers-drug-gene-light-based-therapy-tumor-0725>
- Dec 2015 – *MIT News* article: “A new way to deliver microRNAs for cancer treatment”. <https://news.mit.edu/2015/micrna-shrink-tumor-cancer-treatment-1207>
- Mar 2015 – *MIT News* article: “New nanodevice defeats drug resistance”. <https://news.mit.edu/2015/nanodevice-defeats-cancer-drug-resistance-0302>